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3 ABBREVIATIONS
Bmx bone marrow tyrosine kinase gene in chromosome X
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EMSA electrophoretic gel-mobility shift assay
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ERK extracellular-signal regulated kinase
GH growth hormone
GM-CSF granulocyte-macrophage colony stimulating factor
IFN interferon
IL interleukin
JH Jak homology
Jak Janus kinase
JNK c-Jun NH2-terminal kinase
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MAPK mitogen-activated protein kinase
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SH Src homology
STAT signal transducer and activator of transcription
SCID severe combined immunodeficiency
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VEGF vascular endothelial growth factor
Xid X-linked immunodeficiency
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4 SUMMARY
Extracellular signals regulate the functions of cells of multicellular organisms, such as
proliferation, differentiation and apoptosis. Many of these signals are transduced into cells
through transmembrane receptors that link ligand binding to activation of intracellular
signaling pathways. One of the central mechanisms used in transmembrane signaling is protein
tyrosine phosphorylation. In mammals, approximately 100 different tyrosine kinases mediate
this function. Given the central role of tyrosine kinases in cellular responses, understanding the
regulation and normal function of tyrosine kinases is of critical importance. In the current work,
signaling by members from the Jak and Btk/Tec non-receptor tyrosine kinase families was
analyzed. Aberrant function of kinases from both families has been implicated in malignant
growth of cells.
The Jak kinases are critical mediators of cytokine-induced signaling. The binding of
cytokine to its receptor results in activation of cytokine receptor-associated Jak kinases, and
initiation of a number of different signaling pathways. In one such pathway, a group of
transcription factors termed Signal Transducers and Activators of Transcription, Stats, are
activated. Stats have been found essential in regulating cytokine-induced responses in the
target cells. In addition, Btk/Tec tyrosine kinases are activated through cytokine receptors. In
the current work, the Bmx tyrosine kinase, a member of the Btk/Tec family, was found to
activate Stat transcription factors. The identification of Stats as potential substrates for Bmx
was the first signaling event characterized for the Bmx kinase.
The Jak kinases have a characteristic domain structure consisting of a tyrosine kinase
domain and a catalytically inactive pseudokinase domain, whose function has been unknown.
In the current work, the function of the pseudokinase domain was analyzed in Jak2 and Jak3
kinases. The pseudokinase domain was found to suppress the basal activity of Jak2 and Jak3 in
the absence of cytokine stimulation. The pseudokinase domain-mediated inhibition of Jak2
was independent of additional regulatory proteins, indicating autoinhibition of Jak2 by its
pseudokinase domain. The pseudokinase domain inhibited the catalytic activity of Jak2 by
lowering its maximal velocity (Vmax). Distinct regions in the pseudokinase domain were
identified that mediate the inhibition, and using molecular modeling the inhibitory regions
were located mainly to the C-terminal lobe of the pseudokinase domain.
The pseudokinase domain was also required for cytokine-inducible Jak activation, and
in the absence of a pseudokinase domain, Jaks were unresponsive to cytokine stimulation. The
results support a model, where the pseudokinase domain is part of both the uninduced and
cytokine-induced Jak-receptor complex and acts as a cytokine-inducible switch to link
cytokine binding to Jak activation. During ligand-induced receptor dimerization, the inhibitory
kinase-pseudokinase domain interaction is relieved resulting in a new interaction between two
kinase domains and increased Jak activity. The results from the current work identify a novel
way of regulation of Jak activity, which adds to the understanding of the autoregulatory
mechanisms of tyrosine kinases.
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5 INTRODUCTION
5.1 Type I and type II cytokines
The cellular functions of multicellular organisms, such as growth, differentiation and
apoptosis, are regulated by signals from the extracellular environment. In mammals, direct
cell-cell contacts, cell-matrix contacts or locally or systemically acting soluble mediators
provide the essential signals for the cells. One important group of signals for many cell types is
provided by cytokines.
Cytokines are a large and diverse group of secreted, usually locally acting,
glycoproteins, which mediate intercellular communication by binding to their specific
receptors on the surface of a target cell. The term “cytokine” is loosely defined. One way to
classify cytokines is based on their structural and functional properties and the receptor
molecules they bind to. Growth factors, such as epidermal growth factor (EGF) and
platelet-derived growth factor (PDGF), utilize receptors with intrinsic tyrosine kinase activity,
termed receptor tyrosine kinases (RTKs), while members of the transforming growth factor-β
(TGF-β) superfamily utilize receptors with serine/threonine kinase activity. Other subsets of
cytokines include the tumor necrosis factor (TNF) family and the chemokine family.
Sometimes the term “cytokine” is used only for factors, whose main targets are the
hematopoietic cells, and are thus called the hematopoietic cytokines. The hematopoietic
cytokines, together with structurally related cytokines acting for example in the neural system,
are collectively called type I cytokines and include interleukins (IL) -2, -3, -4, -5, -6, -7, -9, -11,
-12, -13, 15, -21, -23, erythropoietin (EPO), thrombopoietin (Tpo), prolactin (PRL), growth
hormone (GH), thymic stromal lymphopoietin (TSLP), ciliary neurotrophic factor (CNTF),
oncostatin M (OSM), leukaemia inhibitory factor (LIF), cardiotorphin-1 (CT-1),
neurotrophin-1 (NNT-1)/B-cell-stimulating factor-3 (BSF-3), and colony-stimulating factors
for granulocytes (G-CSF) and granulocyte-macrophages (GM-CSF) (Bazan, 1991).
Interferons (IFN) and IL-10 constitute an additional family related to type I cytokines termed
type II cytokine family. IL-19, -20, -22, and -24 have been recently identified as IL-10-related
cytokines.
The type I and type II cytokines share an α-helical three-dimensional structure. The
type I cytokines typically consist of four α-helices, designated from A to D and connected by
short loops (Bazan, 1991; Boulay and Paul, 1992; Rozwarski et al., 1994). The type II
cytokines, IFN-γ and IL-10, contain 6 α-helices instead of four (Ealick et al., 1991; Zdanov et
al., 1995). The helical cytokines function usually as monomers, but IFN-γ and IL-10 are dimers
(Walter et al., 1995; Josephson et al., 2001). The receptors utilized by type I and II cytokines
are structurally related and form the hematopoietic receptor superfamily (Bazan, 1990).
Importantly, receptors of the hematopoietic receptor superfamily share common mechanisms
for signal transduction, which have been the subject of the current work. From now on, the term
“cytokine” is used to refer to factors, which signal through the hematopoietic cytokine
receptors, and these receptors, in turn, are referred to as “cytokine receptors”.
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5.1.1 Biological effects of cytokines
Practically all cells of the body are influenced by cytokines, but the main function of
cytokines is in the hematopoietic system. The hematopoietic cells critically require cytokines
for proliferation and development from the hematopoietic stem cell (hematopoiesis, Figure 1)
(reviewed in Arai et al., 1990; Watowich et al., 1996). In addition to hematopoiesis, the
cytokines regulate immune functions of mature hematopoietic cells, such as mediation of
immune responses to viral, bacterial, fungal and parasitic infections, inflammatory response
and antibody production. Outside the hematopoietic system, for example IFNs regulate the
responses of nearly all cells towards viral and bacterial infections. CNTF exclusively functions
in the nervous system by supporting the survival of ciliary and motor neurons (reviewed in
Taga and Kishimoto, 1997). LIF functions as a cholinenergic differentiation factor in the
nervous system as well, but can also maintain the undifferentiated state of embryonic stem (ES)
cells (reviewed in Kishimoto et al., 1994).
A characteristic feature of cytokines is their functional pleiotropy and redundancy. It
was initially thought that each cytokine mediates a specific effect on its target cells, but now it
is known that most cytokines exert a variety of biological effects on multiple tissue and cell
types (Kishimoto et al., 1994). One cytokine can induce growth on some cell types and
differentiation on other cells, while a single cell type can respond for example by proliferating
to multiple different cytokines. The functional pleiotropy and redundancy of the cytokines can
now be partially explained by the utilization of shared receptors chains (Kishimoto et al., 1994;
Taga and Kishimoto, 1997). Most cytokine receptors consist of a ligand binding chain that is
specific to each cytokine, and a common signal transducing chain utilized by many different
cytokines.
Signaling through the Jak/Stat pathway: Regulation of tyrosine kinase activity 11
B cell
Stem cell
MonocyteGranylocyte
Mast cell / basophil
Eosinophil
Red blood
cell
Megakaryocyte
Myeloid stem cell
Pre-T cellPre-B cell
Lymphoid stem cell
T cell
SCF
IL-3, IL-6
IL-1, GM-CSF
IL-2, IL-4
IL-7, IL-9
IL-10, IL-12
IL-7, IL-6
IL-1
IL-3, IL-5
GM-CSF
CSF-1
IL-3
GM-CSF
IL-7, IL-1
IL-2, IL-6
SCF
IL-3, IL-6
IL-1
IL-3
GM-CSF
Tpo
IL-3
IL-4
IL-3
Epo
G-SCF
IL-3, IL-4
IL-5, IL-6
IL-7, IFN-
Figure 1. Hematopoiesis
5.2 The cytokine receptor superfamily
5.2.1 Cytokine receptors are composed of multiple chains
Cytokine receptors are membrane glycoproteins that have an extracellular domain of
variable length, a single transmembrane domain and an intracellular region (Figure 2). The
extracellular domains of cytokine receptors show structural similarity, which is the basis for
their classification into the cytokine receptor superfamily (Bazan, 1989; D’Andrea et al., 1989;
Gearing et al., 1989; Fukunaga et al., 1990; Goodwin et al., 1990; Idzerda et al., 1990; Itoh et
al., 1990). The intracellular regions of cytokine receptors do not contain intrinsic catalytic
activity, but link ligand binding to activation of signal transduction by associating with a
number of signaling proteins. The mechanisms of signal transduction are shared between the
receptors, and thus, in addition to structural similarity, the cytokine receptors are also
functionally related (reviewed in Ihle et al., 1995).
The cytokine receptors can be organized into subgroups by the number of receptor
subunits and the use of common signaling chains (Figure 2, Table 1). One cytokine receptor
subfamily is composed of single chain receptors (EPO, GH, PRL, TPO) (Yoshimura and
Misawa, 1998). Other subfamilies utilize common signal transducing chains, which associate
with ligand-specific receptor chains to form functional, high-affinity receptor complexes. One
subfamily signals through a common gp130 or gp130-like signaling chain in combination with
a ligand-specific subunit (reviewed in Taga and Kishimoto, 1997). IL-3, IL-5 and GM-CSF
bind to their ligand-specific α-chains and by associating with a common β-chain form a
functional, high-affinity receptor (reviewed in Miyajima et al., 1993). Another subfamily
forms a complex with a common γ-chain, γc. In addition to γc, the IL-2 receptor consists of a
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Cytokine receptor superfamily Cytokines
Type I cytokine receptors
Cytokines whose receptors share γc, as the signaling
chain
IL-2, IL-4, IL-7, IL-9, IL-13+, IL-15, IL-21, TSLP^^
Cytokines whose receptors share βc, as the signaling
chain
IL-3, IL-5, GM-CSF
Cytokines whose receptors share gp130 or a related
protein, as the signaling chain
IL-6, IL-11, IL-12*, IL-23, LIF, OSM, CNTF, CT-1,
G-CSF, Leptin*, ^NNT-1/BSF-3
Cytokines utilizing single chain receptors, which bind
ligand and function as the signaling chain
GH, EPO, PRL, TPO
Type II cytokine receptors
Cytokines utilizing two or more distinct subunits
IFN-γ, IFN-αs/β/ω/Limitin, IL-10, IL-19, IL-20, IL-22,
mda-7/IL-24, AK155/IL-26, FISP
Table 1. The cytokine receptor superfamily. +IL-13 does not share γc but uses IL-4Rα, ^^TSLP binds to a
related but γc independent receptor, *IL-12 and leptin do not share gp130, but their receptors are related to
gp130, ^NNT-1/BSF-3 binds to IL-12Rβ1, mda-7 (melanoma differentiation-associated gene), NNT-1
(neurotrophin-1), BSF-3 (B-cell-stimulating factor-3), TSLP (thymic stromal lymphopoietin) (modified from
Ihle et al., 1995; Schindler, 2002).
β-chain unique to IL-2 and a ligand-binding α-chain required for formation of the high-affinity
IL-2 receptor (reviewed in Leonard et al., 1995). The biological functions within the receptor
subfamilies are very similar, and the utilization of common signaling chains explains for the
functional redundancy characteristic for cytokines. Type II receptors are related to the
above-described type I cytokine receptors and include the receptors for IFNs, IL-10 and a
newly identified group of IL-10-related cytokines, IL-19, IL-20, IL-22, IL-24 and IL-26. These
receptors consist of at least two different subunits, both of which are used for signaling, but
only one binds the cytokine (reviewed in Kotenko and Pestka, 2000).
5.2.2 The extracellular domains of cytokine receptors are structurally
related
The extracellular domains of type I cytokine receptors are characterized by an
approximately 200 amino acids long homologous region with sequence identity between 14 to
25% (reviewed in Cosman et al., 1990). This region is called the cytokine or hematopoietic
receptor homology (CHR) domain, and it is composed of two domains, both approximately 90
amino acids long (Bazan, 1990). These 90 amino acid domains are related to fibronectin (FBN)
type III domains, often found in cell surface proteins with adhesive functions (Bazan, 1990).
The FBN type III domains consist of seven β-strands forming a β-sandwich motif. The
N-terminal domain usually contains two pairs of conserved cysteines, which contribute to the
tertiary structure of the domain by forming disulfide bridges (Bazan, 1990). The C-terminal
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Figure 2. Schematic presentation of cytokine receptor families.
domain contains a conserved WSXWS motif. The three-dimensional structures of the
extracellular domains of various cytokine receptors with ligands have shown that the hinge
region between the two motifs of a CHR domain forms the binding interface for cytokines (de
Vos et al., 1992; Walter et al., 1995; Livnah et al., 1996Chow et al., 2001). The WSXWS motif
is located near the hinge region, but does not make contact with the cytokine, but instead
interacts with the N-terminal CHR domain stabilizing the overall CHR structure (Quelle et al.,
1992; Yoshimura et al., 1992; Hilton et al., 1996; Syed et al., 1998). The type II cytokine
receptors have the similar extracellular domain structure as type I receptors, but differ by a
unique cysteine distribution and lack of the WSXWS motif. The receptors may contain
additional protein domains, such as FBN III or Immunoglobulin (Ig) domains.
5.2.3 The intracellular domains of cytokine receptors mediate signaling
functions
The cytokine receptors do not contain any catalytic domains. The cytoplasmic regions
of the cytokine receptors are less conserved than the extracellular regions, but the
membrane-proximal parts show limited sequence similarity (Murakami et al., 1991). Two
conserved regions are referred to as box1 and box2 motifs (Murakami et al., 1991). The
consensus for the box1 motif is Al-Ar-Pro-X-Al-Pro-X-Pro or Ar-X-X-X-Al-Pro-X-Pro,
where Al= aliphatic, Ar=aromatic and X is any amino acid (reviewed in Ihle et al., 1995). Box1
is located within the first 20 amino acids of the cytoplasmic domain. The box2 motif is
characterized by a stretch of hydrophobic amino acids followed by several charged amino
acids. A conserved tryptophane residue is located between box1 and 2. Mutations of the box1
proline residues, of the conserved tryptophane and of residues in the box2 motif have been
found to inactivate the receptors examined (Murakami et al., 1991; Barge et al., 1996; Haan et
al., 2000). Thus, the membrane-proximal regions are critical for overall receptor function.
Especially, the membrane proximal regions have been found to contribute to cytokine-induced
growth responses of the cells (He et al., 1994; Howard et al., 1995; Jiang et al., 1996).
The membrane distal regions of cytokine receptors also mediate important signaling
functions of receptors. The membrane distal part of the G-CSFR has been found to mediate
induction of neutrophil-specific genes, and contribute to granulocytic differentiation as well as
G-CSF-induced proliferation (Fukunaga et al., 1993; Dong et al., 1994; McLemore et al.,
2001). The membrane distal regions contain tyrosine residues that become phosphorylated
upon cytokine stimulation, and serve as docking sites for Src homology 2 (SH2) containing
signaling proteins. The membrane distal region of the EPOR contains a binding site for the SH2
containing protein tyrosine phosphatase (SHP-1) essential for termination of EPOR signaling
(Yoshimura et al., 1990; D’Andrea et al., 1991; Klingmuller et al., 1995). In addition, binding
sites for many other signaling proteins have been located within the cytoplasmic domains of
cytokine receptors. Jak tyrosine kinases associate with the membrane-proximal box1/box2
motifs (Frank et al., 1994; Quelle et al., 1994; Hackett et al., 1995; Howard et al., 1995Kirken
et al., 1995; Lebrun et al., 1995b; Malabarba et al., 1995; Nicholson et al., 1995; Tanner et al.,
1995; Jiang et al., 1996; Yan et al., 1996a), while the binding sites for Stat transcription factors
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are located in the membrane-distal regions (Greenlund et al., 1994; Fujii et al., 1995; Kirken et
al., 1995; Lebrun et al., 1995a; Nicholson et al., 1995; Stahl et al., 1995; Hansen et al., 1996;
Quelle et al., 1996; Weber-Nordt et al., 1996; Yi et al., 1996; Pezet et al., 1997).
5.2.4 Cytokine-induced receptor dimerization/oligomerization
In receptor activation, the function of the ligand is to induce
dimerization/oligomerization of receptor subunits, which enables efficient interaction of the
cytoplasmic domains of the receptor chains and of the receptor-associated signaling proteins
(reviewed in Heldin, 1995). Each cytokine contains at least two binding sites for its receptor, or
alternatively, the cytokine can bind the receptor as a homodimer, as in the case of IFN-γ. The
three-dimensional structures of cytokines bound to the extracellular domains of their receptors,
have revealed mechanisms how cytokines bind to and mediate activation of their specific
receptors (reviewed in Mott and Campbell, 1995; Wells, 1996).
The crystal structure of the complex between the human GH and the extracellular
domain of its receptor (GHbp) showed that GH induces homodimerization of its receptor by
simultaneously binding two identical receptor subunits (de Vos et al., 1992). Two distinct sites
in one GH molecule bind identical CHR sites in both of the two receptors, although the two
binding sites on GH have no structural similarity (de Vos et al., 1992). The binding of GH to the
GHbp occurs sequentially; one GHbp molecule forms first a complex with GH, followed by
binding of the second GHbp (Cunningham et al., 1991).
In certain other receptors other domains, in addition to CHR, make contacts with the
cytokine. For example, gp130 ligands contain three distinct epitopes interacting with different
receptors (reviewed in Bravo and Heath, 2000). One site is involved in interaction with a
non-signaling receptor subunit, a second site is engaged with CHR of gp130, and a third site
with a second signaling subunit (gp130, LIF-R or OSM-R). When the ligand makes two
contacts with gp130, one contact is mediated via an Ig-like domain (IGD) located on the
C-terminal side of CHR. Thus, ligands with two binding sites for gp130 will form hexameric
signaling complexes (2:2:2 gp130: ligand: nonsignaling chain), and ligands binding just one
copy of gp130 signal through trimeric complexes.
IFN-γ interacts as a homodimer with the ligand-binding IFNγRI chain, and induces
dimerization of the receptor subunits (Walter et al., 1995). However, the two IFNγRI chains in
the dimer do not interact with each other, as shown by the crystal structure of the complex
between IFN-γ and its soluble high-affinity receptor (Walter et al., 1995). This makes the
IFNγRI dimer inactive, although the cytoplasmic domains bind signaling proteins (Kotenko et
al., 1995). Activation of IFNγ receptor requires association of a second chain, IFNγRII, to form
a tetrameric complex (Kotenko et al., 1995).
The structures for different cytokine-receptor complexes have shown that although the
ligand-receptor interfaces are large, a cluster of few amino acids forms an energetic “hot spot”
in the center of the binding interface responsible for the binding affinity (reviewed in Wells,
1996; Bravo and Heath, 2000). The most significant contacts are hydrophobic, and contribute
to stabilization of the interaction mainly by decreasing the dissociation rate of the complex.
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These findings have suggested that it might be possible to design small molecule
agonists/antagonists that would interact with the few functional receptor epitopes that mediate
cytokine-receptor interactions.
5.2.5 Cytokine-induced conformational change leads to receptor
activation
Even though cytokine-induced dimerization/oligomerization of receptor chains is
required for receptor activation, dimerization as such is not sufficient for activation. There is
evidence that receptor dimers can adopt also inactive conformations (reviewed in Ballinger and
Wells, 1998). The crystal structure of the extracellular domain of the EPO receptor (EPObp) in
complex with EPO or two different EPO-mimetic peptides exhibiting either agonist or
antagonist activity showed that all three ligands formed receptor homodimers. However, the
relative orientation of receptor chains in dimers with EPO mimetics differed from that with
EPO (Livnah et al., 1998; Syed et al., 1998). This interdomain orientation was found critical for
optimal signaling, most likely affecting the relative orientation of the cytoplasmic domains as
well. Thus, dimerization of receptor subunits may result in different types of receptor
complexes, either competent or incompetent to connect to intracellular signaling.
The crystal structure of the unliganded extracellular domain of EPObp further showed
that two EPObp molecules formed a dimer in the absence of ligand, but this dimer was inactive
(Livnah et al., 1999). The C-terminal ends of EPObp molecules at the predicted start site of the
transmembrane region were 73 Å apart, compared to 39 Å in the EPObp-EPO agonist complex
(Livnah et al., 1999). In addition, in vivo data has confirmed that distinct dimers exist for
unliganded and ligand-bound EPO receptors, and that ligand binding modulates the
conformation of the cytoplasmic regions in a receptor dimer to allow signal transduction
(Remy et al., 1999). Thus, the binding of a cytokine induces dimerization or oligomerization of
receptor chains, with a concomitant change in receptor conformation, thereby resulting in
receptor activation and initiation of downstream signaling pathways (Figure 3).
5.3 Tyrosine phosphorylation as a mechanism of cellular
signaling
Protein tyrosine
phosphorylation,
discovered in 1979, is the
major mechanism of
transmembrane signaling
mediated by virtually all
types of transmembrane
receptors (reviewed in
Hunter, 1998, 2000). The
overall level of tyrosine
phosphorylated proteins in
vertebrate cells is very low,
approximately 0.05%,
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Figure 3. Schematic presentation of EPOR dimers (modified from
Livnah et al., 1999).
compared to phosphoserine in 90% of cellular proteins (reviewed in Hunter, 1998). Tyrosine
phosphorylation as a signaling mechanism is only present in multicellular organisms from
Dictyostelium to mammals, but not in yeast or lower organisms.
Tyrosine phosphorylation is mediated by protein tyrosine kinases (PTKs), of either
receptor (RTKs) or non-receptor type (NRTKs) (reviewed in Hubbard and Till, 2000). RTKs
are single spanning transmembrane proteins containing intrinsic tyrosine kinase domains in
their cytoplasmic domains. NRTKs contain various protein domains, which recognize, for
example, a phosphorylated tyrosine (SH2, PTB) or polyproline (SH3) in the context of a short
linear peptide or for example phospholipid (PH). NRTKs can associate through their protein
domains or via lipid modification to plasma membrane or interact with transmembrane
receptors linking ligand binding to downstream signaling. Mammals contain 32 NRTKs,
forming at least ten distinct families (Figure 4).
Ligand binding induces receptor dimerization and a conformational change of the
receptor chains resulting in activation of intrinsic or associated PTKs. The receptor becomes
phosphorylated on its tyrosine residues, and these residues recruit phosphotyrosine binding
proteins, such as PTKs, adapter proteins, protein tyrosine phosphatases (PTPases),
transcription factors etc. to the transmembrane receptor. These proteins form larger complexes
through interaction of their modular signaling domains. Thus, the ability of certain protein
domains to specifically recognize phosphotyrosine formed upon ligand binding results in
formation of a high local concentration of signaling proteins at the plasma membrane, which
enables activation of multiple signaling pathways. These signaling pathways are attenuated by
the action of PTPases or regulatory proteins, through receptor endocytosis, feedback serine
phosphorylation or phosphorylation-dependent ubiquitination and degradation.
The catalytic domains in PTKs are approximately 300 amino acids long and contain
considerable sequence conservation of catalytically important residues (reviewed in Hanks et
al., 1988). The three-dimensional structures of kinase domains are highly conserved being
composed of two lobes (reviewed in Hubbard and Till, 2000). The N-terminal (N) lobe is
smaller and consists of β-sheets except for one α-helix, αC, which has important regulatory
functions (reviewed in Huse and Kuriyan, 2002). The C-terminal (C) lobe is predominantly
α-helical. ATP binds in a cleft formed between the two lobes, and the substrate binds across the
nucleotide-binding pocket.
A sequence called activation loop (A-loop) in PTK domains contains tyrosine residues
with a regulatory function. The PTK domain can exist in two distinct conformations. The active
conformations of PTK domains are extremely similar; the A-loop tyrosines are phosphorylated
and the A-loop lies out from the catalytic cleft. In the inactive conformation, the
unphosphorylated A-loop may occupy the catalytic cleft preventing ATP or substrate binding.
The inactive conformations of PTK domains differ considerably, and the knowledge of the
inactive conformation has turned out to be important in the design of kinase inhibitors
(Schindler et al., 2000). Several distinct mechanisms are utilized to keep the kinase domains
inactive (reviewed in Huse and Kuriyan, 2002). These may involve interactions with other
protein domains in the molecule, which often directly or indirectly induce conformational
Signaling through the Jak/Stat pathway: Regulation of tyrosine kinase activity 17
18 Pipsa Saharinen
changes in the αC helix in the N lobe, which in turn modulates the A-loop conformation.
Regulatory mechanisms of tyrosine kinases are discussed more extensively in chapter 9.6 in
Discussion.
5.4 Signaling through cytokine receptors, the Jak/Stat pathway
5.4.1 Background
Cytokine receptors lack intrinsic tyrosine kinase activity, but cytokine binding triggers
rapid tyrosine phosphorylation of cytoplasmic signaling proteins. In the beginning of the
1990s, rapid progress was made in elucidating the events leading to altered gene expression
from a cytokine-bound receptor. Tyrosine kinases belonging to a new tyrosine kinase family
were cloned using low-stringency hybridization and degenerate PCR, and named as Jak1, Jak2,
Jak3 and Tyk2 (for Just another kinase or Janus) kinases (Wilks, 1989; Firmbach-Kraft et al.,
1990; Krolewski et al., 1990; Wilks et al., 1991; Harpur et al., 1992; Silvennoinen et al., 1993c;
Kawamura et al., 1994; Rane and Reddy, 1994; Takahashi and Shirasawa, 1994; Witthuhn et
al., 1994). Using cell lines defective in IFN responses, Jaks were identified as mediators of IFN
signaling (Velazquez et al., 1992; Muller et al., 1993; Silvennoinen et al., 1993a; Watling et al.,
1993), and subsequently, found to be activated by a vast number of other cytokines as well
(Table 2) (Argetsinger et al., 1993; Witthuhn et al., 1993; Johnston et al., 1994; Lutticken et al.,
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Figure 4. Mammalian non-receptor tyrosine kinase families.
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1994; Miyazaki et al., 1994Russell et al., 1994; Stahl et al., 1994; Witthuhn et al., 1994;
Johnston et al., 1995a). The Signal Transducers and Activators of Transcripion, Stats, were
first identified as DNA-binding proteins in IFN-regulated gene expression (Fu, 1992; Fu et al.,
1992; Schindler et al., 1992a; Schindler et al., 1992b; Shuai et al., 1992; Veals et al., 1992;
Shuai et al., 1993, reviewed in Darnell et al., 1994). Following cloning of the IFN-activated
Stat1 and Stat2, five additional members of the Stat transcription factor family were cloned and
found to be activated by a different set of cytokines (Table 2) (Akira et al., 1994Hou et al.,
1994; Tian et al., 1994; Wakao et al., 1994; Yamamoto et al., 1994; Zhong et al., 1994a, b;
Azam et al., 1995; Gouilleux et al., 1995; Hou et al., 1995; Liu et al., 1995; Mui et al., 1995a;
Pallard et al., 1995; Quelle et al., 1995a; Wakao et al., 1995; Lin et al., 1996).
The finding of Jaks and Stats as mediators of cytokine signaling led to the concept of
the Jak-Stat signaling pathway, formed by Jak tyrosine kinases and their substrates, Stats,
which at the same time are signal transducer proteins and transcriptional activators, hence the
name. The Jak-Stat pathway turned out to be unique being formed of only two components.
Animal models defective in individual Jaks and Stats have revealed essential and
non-redundant roles for Jak and Stat proteins in cytokine signaling, in rather well agreement
with the specific association of different Jaks and different Stats with only a subset of cytokine
receptors (reviewed in Leonard and O’Shea, 1998). In addition to cytokine receptors, Jaks and
Stats have been found to be activated by a variety of other receptors, such as growth factor
receptors for EGF (Silvennoinen et al., 1993b), PDGF (Vignais et al., 1996), HGF (Boccaccio
et al., 1998) and VEGF (Korpelainen et al., 1999; Bartoli et al., 2000), and through a seven
transmembrane domain receptor AT1 (Marrero et al., 1995) (Table 2), but the role of Jak/Stat
activation in these receptors is not well-defined. The Jak/Stat pathway exists also in lower
organisms, such as Drosophila melanogaster and Coenorhabditis elegans (Zeidler et al.,
2000). In Dictyostelium discoiduem, a Stat molecule has been characterized, which is activated
via a seven transmembrane domain receptor (Araki et al., 1998, reviewed in Aubry and Firtel,
1999).
5.4.2 Overview of signaling by the Jak/STAT pathway
The sequence of events leading to altered gene expression from a cytokine-bound
receptor begins with activation of the receptor-associated Jaks, which is critical for further
signal transduction (reviewed in Ihle et al., 1995; Schindler, 1999; Imada and Leonard, 2000;
Rane and Reddy, 2000; Candotti et al., 2002). Cytokine receptors composed of two or more
different chains activate at least two different Jak kinases, while single chain receptors activate
typically Jak2.
The activated Jak kinases phosphorylate tyrosine residues in the intracellular domains
of receptor chains, thus creating docking sites for SH2 domain-containing signaling proteins,
such as Stats, which reside latent in the cytoplasm in the absence of cytokine stimulation
(reviewed in Darnell et al., 1994; Horvath and Darnell, 1997). Jaks phosphorylate the
receptor-associated Stats, which subsequently dissociate from the receptors, dimerize through
their SH2 domains and translocate to nucleus (Shuai et al., 1994; Greenlund et al., 1995). The
Stat dimers bind to specific elements in the promoter regions of their target genes to induce
transcription together with a number of other transcriptional co-activators (Figure 5). This
simplified version of Jak/Stat signaling is becoming more complex as regulators of this
pathway are identified (reviewed in Yasukawa et al., 2000). Also, there is evidence for cross-talk
between different signaling pathways. For example, GH induces EGFR signaling by activating
Jak2, which phosphorylates the Grb2 binding site in EGFR (Yamauchi et al., 1997).
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Cytokine /growth factor Jak kinase activated Stats activated
Type I cytokines
Cytokines whose receptors share γc
IL-2, IL-7, IL-9, IL-15 Jak1, Jak3 Stat5a, Stat5b, Stat3
IL-4 Jak1, Jak3 Stat6, Stat5a, Stat5b
IL-13 Jak1, Jak2, Tyk2 Stat3, Stat6
IL-21 Jak1, Jak3 Stat1, Stat3, Stat5
TSLP none Stat5
Cytokines whose receptors share βc
IL-3, IL-5, GM-CSF Jak2 Stat5a, Stat5b
Cytokines whose receptors share gp130
IL-6, IL-11, LIF, OSM, CNTF, CT-1 Jak1, Jak2 Stat1, Stat3
IL-12 Tyk2, Jak2 Stat4
Leptin Jak2 Stat3
IL-23 ? Stat4
NNT-1/BSF-3 Jak1, Jak2 Stat1, Stat3
G-CSF Jak1, Jak2 Stat3
Cytokines with homodimeric receptors
GH Jak2 Stat5a, Stat5b, Stat3
PRL Jak2 Stat5a, Stat5b
EPO, TPO Jak2 Stat5a, Stat5b
Type II Cytokines
IFN-γ Jak1, Jak2 Stat1, Stat2
IFN-αs/β/ω/Limitin Jak1, Tyk2 Stat1, Stat2, Stats3-6
IL-10 Jak1, Tyk2 Stat3
IL-19, IL-20, IL-24 ? Stat1,Stat3
IL-22 Jak1, Tyk2 Stat1, Stat3, Stat5
Growth factors
EGF Jak1, Jak2 Stat1, Stat3, Stat5
PDGF Jak1, Jak2 Stat1, Stat3, Stat5, Stat6
VEGF ? Stat1, Stat3, Stat5, Stat6
HGF ? Stat1, Stat3
CSF-1 Jak1, Tyk2 Stat1, Stat3, Stat5
Seven transmembrane domain receptors
Angiotensin II AT1 Jak2, Tyk2 Stat1, Stat2
Table 2. Activation of Jaks and Stats. In certain receptors, the Jaks and Stats with essential signaling
functions discovered to date are indicated in bold (modified from Leonard and O’Shea, 1998; Kisseleva et
al., 2002; Schindler, 2002).
5.4.3 Type I and type II interferons and two different types of Stat
signaling
Signaling by IFNs represents two different concepts found in Stat signaling, (Figure 5)
(reviewed in Kotenko and Pestka, 2000). The interferons can be divided into two groups, type I
(IFN-αs, IFN-β, IFN-ω and IFN-τ) and type II interferons (IFN-γ). IFN-αRI associates with
Tyk2 and IFN-αRII with Jak1, whereas IFN-γRI binds Jak1 and IFN-γRII Jak2. Ligand binding
induces activation of associated Jaks, and subsequent tyrosine phosphorylation and activation
of Stats (Velazquez et al., 1992; Muller et al., 1993; Silvennoinen et al., 1993a; Watling et al.,
1993). IFN-γ predominantly activates Stat1, which forms homodimers and binds to a so-called
GAS (IFN-γ activated sequence) element in the target promoters (Decker et al., 1991; Lew et
al., 1991; Shuai et al., 1992). Type I IFNs activate Stat1 and Stat2, which form heterodimers,
and the dimers further associate with a third protein, IRF-9 (p48), to form the ISGF3 complex
(Dale et al., 1989a; Fu et al., 1992Schindler et al., 1992b). The DNA binding specificity of
ISGF3 differs from that of other Stats, and it specifically interacts with promoters containing
ISRE (IFN-stimulated response element) elements (Dale et al., 1989b; Kessler et al., 1990).
The Stat1, Stat3, Stat4, Stat5a/b or Stat6 homodimers, or heterodimers, which are formed
between Stat1 and Stat3, or between Stat5a and Stat5b, bind DNA sequences that are very
similar to the GAS sequence, and most of the above-mentioned dimers can bind to GAS
(reviewed in Decker et al., 1997). However, the ISGF3 complex containing the Stat1-Stat2
heterodimer binds only ISRE sequences. Thus, ISRE elements appear to be a unique feature of
type I IFN-induced signaling.
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Figure 5. Jak/Stat signaling through the IFNγ and IFNα receptors.
5.5 Jak tyrosine kinases
5.5.1 Expression of Jak kinases
The Jak family of non-receptor protein tyrosine kinases comprises of four mammalian
members: Jak1, Jak2, Jak3 and Tyk2. In humans, the gene for Jak1 is located in chromosome
1p31.3, the Jak2 gene in chromosome 9p24, the Jak3 gene in chromosome 19p13.1 and the
gene for Tyk2 in chromosome 19p13.2 (Firmbach-Kraft et al., 1990; Pritchard et al., 1992;
Kumar et al., 1996; Riedy et al., 1996). The murine genes are located on chromosomes 4
(Jak1), 19 (Jak2) and 8 (Jak3 and Tyk2). Jak2 has two transcripts, and multiple alternatively
spliced forms of Jak3 have been detected (Rane and Reddy, 1994; Ihle et al., 1995; Lai et al.,
1995; Gurniak and Berg, 1996), one of which lacks kinase activity (Lai et al., 1995), but the
functional significance of these variant transcripts is not known. In addition, in Drosophila
melanogaster, the hopscotch (hop) locus encodes a Jak homologue, Hop (Binari and Perrimon,
1994). In slime mold Dictyostelium discoiduem kinases (DPYK3 and DPYK4) with tandem
kinase domain structure have been cloned, but overall they are not highly homologous to Jaks
(Adler et al., 1996).
The Jak kinases range in molecular mass between 110-140 kDa. Jak1, Jak2 and Tyk2
are ubiquitously expressed, but expression of Jak3 is more restricted. The expression of Jak3 is
constitutive in NK cells and thymocytes and inducible in T cells, B cells and myeloid cells
(Kawamura et al., 1994; Rane and Reddy, 1994; Musso et al., 1995; Tortolani et al., 1995;
Gurniak and Berg, 1996; Sharfe et al., 1997). In addition to hematopoietic cells, Jak3 is also
expressed in vascular smooth muscle cells and endothelium (Verbsky et al., 1996).
5.5.2 The tandem kinase domain motif is a unique feature in Jak kinases
The domain structure of mammalian Jaks and Drosophila Hop is conserved (Figure 6).
Based on sequence conservation, the Jak kinases are divided into seven Jak homology (JH)
domains starting from the tyrosine kinase domain located at the C-terminus of Jaks and
designated as JH1 (reviewed in Ziemiecki et al., 1994). The hallmark in Jak kinases is the
presence of a tandem kinase domain structure, which is unique among tyrosine kinases
(Hubbard and Till, 2000). The tandem kinase domain structure is composed of the tyrosine
kinase domain, JH1, and a pseudokinase or kinase-like domain, JH2, on the N-terminal side of
JH1. Only the JH1 domain is catalytically active. The tandem kinase domain comprises
approximately 50 % of the entire Jak molecule.
The JH1 domain has all the characteristics of a typical tyrosine kinase domain (Hanks
et al., 1988). JH1 is approximately 300 amino acids long, corresponding to 30 kDa. Mutation of
the conserved lysine directly involved in ATP binding in kinase subdomain II, abrogates kinase
activity (Briscoe et al., 1996; Gurniak and Berg, 1996). The A-loop of Jaks contains a
conserved double tyrosine motif, which is phosphorylated in Jaks in response to cytokine
stimulation. Phosphorylation of A-loop tyrosines in Jaks regulates their catalytic activity, but
the role of these two tyrosines varies between Jak family members (Gauzzi et al., 1996; Feng et
al., 1997; Liu et al., 1997; Zhou et al., 1997). Phosphorylation of the first tyrosine in the double
tyrosine motif is critical for the catalytic activity of Jak1 and Jak2, but it is less important for
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Jak3 activity (Feng et al., 1997; Liu et al., 1997; Zhou et al., 1997). In Jak3, mutation of the
second tyrosine increases catalytic activity, but a similar mutation in Jak1 or Jak2 has no effect
(Feng et al., 1997; Liu et al., 1997; Zhou et al., 1997).
The JH2 domain has sequence similarity to kinase domains, but several of the residues
required for phosphotransferase activity are altered from the canonical motifs, and
consequently, JH2 has been considered catalytically inactive, and this has been confirmed
experimentally (Wilks et al., 1991; Frank et al., 1995; Velazquez et al., 1995). Thus, the JH2
domain is called the pseudokinase or the kinase-like domain. For example, the JH2 domains
lack the third glycine in the conserved GXGXXG motif in kinase subdomain I, which normally
forms the nucleotide binding loop (Hanks et al., 1988). JH2 also lacks the invariant aspartic
acid, functioning as the proton acceptor in the phosphotransfer reaction and located in the
catalytic loop in subdomain VIb (Hanks et al., 1988). Furthermore, JH2 lacks a conserved
phenylalanine in the PEG motif in subdomain VII that is important for binding of the adenine
ring of ATP (Hanks et al., 1988).
At the beginning of the current work, the function of the JH2 domain was not known.
Two reports had been published leaving the role of the JH2 domain unclear. In Tyk2, the JH2
domain had been deleted, resulting in inactivation of the kinase and inability of Tyk2 to
mediate IFN-α signaling (Velazquez et al., 1995), but the deletion of the Jak2 JH2 domain did
not show a similar effect in GH signaling (Frank et al., 1995). During the current work, a
number of investigations were conducted to analyze the function of the JH2 domain, including
those presented in the current work, and are reviewed in chapters 9.3-9.7 in the Discussion.
5.5.3 The N-terminal half of Jak kinases contains a FERM domain
For many years, it was acknowledged that the N-terminal half of Jaks, containing JH
domains 3-7, is unique among tyrosine kinases and does not contain any homology to known
protein domains. However, recent studies based on computational methods indicated the
presence of a SH2-like domain and a band-four-point-one, ezrin, radixin, moesin (FERM)
homology domain in JH3-JH4 and JH4-JH7 regions of Jaks, respectively (Higgins et al., 1996;
Girault et al., 1999; Kampa and Burnside, 2000; Al-Lazikani et al., 2001).
In addition to Jaks, FERM domains are found only in one tyrosine kinase family, the
FAK tyrosine kinases, although the FERM domains are widespread in other proteins (Chishti et
al., 1998). The FERM domain is a 300 amino acid domain, composed of three subdomains that
form a compact clover-shaped structure (Turunen et al., 1998; Hamada et al., 2000; Pearson et
al., 2000). Subdomain A is a ubiquitin-like fold, subdomain B is an acyl-coenzyme A binding
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Figure 6. Schematic domain structure of Jak kinases.
protein-like fold and subdomain C is a PTB or PH fold. The linker between subdomains A and
B, which is at the center of a hydrophobic core, has a critical role in stabilizing the structure of
the FERM domain.
The FERM domains mediate often interactions with cytoplasmic domains of
membrane proteins (Chishti et al., 1998). Also, in Jaks the region required for binding to
cytokine receptors is located within the FERM domain. For Jak3, the minimal region required
for binding to γc is within JH7-JH6 (Chen et al., 1997; Cacalano et al., 1999). The JH7-JH6
region in Jak2 is crucial and sufficient for binding to GM-CSF and GHR (Frank et al., 1995;
Zhao et al., 1995). The JH6-7 domains mediate also specific binding of Jak2 to IFNγRII and
EPOR, but in these receptors the JH3-5 region contributes to binding as well (Kohlhuber et al.,
1997; Huang et al., 2001). Similarly, the Tyk2 region required for binding to IFNαRI has been
mapped to JH7-JH6, but regions within JH3-5 contribute to formation of the receptor-Tyk2
complex (Richter et al., 1998; Yan et al., 1998). Jak1 binds to gp130 through its FERM domain,
and within the FERM domain, the binding site has been located in the loop 4 of the first subunit,
the ubiquitin-like or β-grasp fold (Haan et al., 2001; Hilkens et al., 2001). This region is located
within the JH7 domain in Jak1, and shows considerable sequence differences between Jak
family members, in accordance with differential binding specificity generated by the JH7
domains of Jaks (Haan et al., 2001). In line with the role of the Jak FERM domain in cytokine
receptor interactions, the FERM domain in FAK has been found to mediate binding to EGFR
(Sieg et al., 2000).
The Jak FERM domain has been found to enhance the cell surface expression of certain
cytokine receptors. The Tyk2 JH3-7 region was first found to be required for expression of the
IFNαRI and recently, Jak2 and Jak1 were found to be required for proper folding and/or
processing of EPOR and OSMR, respectively, by associating with the cytoplasmic domains of
the cytokine receptors already in the endoplastic reticulum (ER) (Gauzzi et al., 1997; Huang et
al., 2001; Radtke et al., 2002). The kinase activity of Jaks is not required for promoting receptor
expression, indicating that Jaks are essential structural components of the cytokine receptors.
However, in this respect the cytokine receptors may differ, since Jak3 is not required for
expression of γc (Suzuki et al., 2000).
5.5.4 A SH2-like domain is present in Jak kinases
SH2 domains are common in NRTKs, like in Src and Btk families (Hubbard and Till,
2000). The presence of a SH2 domain in the JH3-4 region of Jaks is supported by several data
including sequence-based predictions of secondary structures as well as multiple alignments of
several SH2 domains from different proteins (Kampa and Burnside, 2000; Al-Lazikani et al.,
2001). However, the SH2 domain of Tyk2 does not contain a key arginine residue required for
phosphotyrosine binding, but instead contains a histidine residue, which is estimated to be
neutral at pH 7 (Al-Lazikani et al., 2001). Thus, the SH2 domain of Tyk2 may have a different
binding specificity, and be unable to bind phosphotyrosine (Al-Lazikani et al., 2001). The
function of the SH2 domain in Jaks is not known, and studies in cultured cells failed to show
any effect upon mutation of the conserved arginine in Jak2 SH2 (Kohlhuber et al., 1997).
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5.5.5 The role of Jak kinases in the initiation of signal transduction
The key step in signaling through cytokine receptors is the activation of Jak kinases.
Jaks are constitutively associated with the membrane-proximal regions of cytokine receptors,
although in some cases Jak-receptor interaction is increased upon ligand binding. In the
absence of ligand, Jaks remain inactive, but ligand-induced conformational change in the
receptor complex leads to Jak activation through reciprocal interaction of two juxta-positioned
Jak kinases (Remy et al., 1999). Jak activation involves auto/transphosphorylation of their
A-loop tyrosines (Gauzzi et al., 1996; Feng et al., 1997; Liu et al., 1997; Zhou et al., 1997). The
Jak kinases do not need other tyrosine kinases for their activation, and supporting this,
homodimerization of two Jak2 kinases has been found to be sufficient for induction of
signaling (Sakai et al., 1995; Nakamura et al., 1996).
In single-chain receptors dimerization of two Jak2 kinases results in induction of Jak2
activity. In receptors composed of multiple chains, Jak activation is a result of interplay
between two different Jak kinases, which has been elucidated to some extent using cell lines
defective in IFN-α and IFN-γ signaling (Muller et al., 1993; Watling et al., 1993). In cells
lacking Jak1, expression of a kinase-inactive Jak1 can sustain substantial IFN-γ-inducible gene
expression, suggesting a structural as well as an enzymatic role for Jak1 in IFN-γ signaling
(Briscoe et al., 1996). On the other hand, kinase-negative Jak2 cannot sustain IFN-γ-inducible
gene expression in cells lacking endogenous Jak2, indicating that catalytic activity of Jak2 is
essential for IFN-γ signaling (Briscoe et al., 1996). In the absence of Jak2, however, Jak1 is
able to induce low level of Stat1 activation (Briscoe et al., 1996).
A kinase domain deletion mutant of Tyk2 can sustain a very low level of
IFN-α-inducible gene expression, while kinase-inactive Jak1 does not, suggesting a major role
for Jak1 in IFN-α signaling (Velazquez et al., 1995). Kinase-inactive form of Tyk2 is also
phosporylated upon IFN-α stimulation in Tyk2 negative cells reconstituted with this Tyk2
mutant (Gauzzi et al., 1996). A role for Tyk2 as an amplifier of cytokine signaling, rather than
as an initiator of signaling, is also suggested by results from Tyk2-deficient mice (Karaghiosoff
et al., 2000; Shimoda et al., 2000). In the cells from Tyk2-/- mice, the immediate signaling
events following IFN-α treatment were present, although reduced, while IFN-α-mediated
responses were totally lacking in Jak1-/- mice (Rodig et al., 1998; Karaghiosoff et al., 2000;
Shimoda et al., 2000). Studies using the Tyk2 negative cell line, 11.1, indicated a structural role
for Tyk2 in mediating formation of the functional IFN-α receptor complex at the cell surface.
The Tyk2 knockout mice, however, did not show a similar result (Gauzzi et al., 1997; Richter et
al., 1998; Yeh et al., 2000). Altogether, these results suggest that Jaks are, to some extent,
interdependent in their activation, but are not functionally symmetrical. Furthermore, Jaks have
also a structural role, in addition to an enzymatic one, in cytokine receptors. One such a role is
the requirement of Jaks for cell surface expression of certain cytokine receptors (Gauzzi et al.,
1997; Yeh et al., 2000; Huang et al., 2001; Radtke et al., 2002).
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5.6 Stats, the signal transducers and activators of transcription
5.6.1 Seven Stat transcription factors are widely expressed
The Stat family of transcription factors contains 7 mammalian members, Stat1, Stat2,
Stat3, Stat4, Stat5a, Stat5b and Stat6 (reviewed in Bromberg and Darnell, 2000). Stats range in
length between 750-900 amino acids. The Stats are clustered in the human genome; Stat1 and
Stat4 are located on human chromosome 2, Stat2 and Stat6 on chromosome 12 and Stat3
together with the two Stat5 genes, Stat5a and Stat5b, on human chromosome 17. Stat5a and
Stat5b are over 90% identical at the amino acid level (Mui et al., 1995b). Mammalian Stats are
all ubiquitously expressed. A unique set of Stats is associated with each cytokine receptor
(Table 2), which is important for the specificity of the induced biological responses. Stats have
also been identified in Drosophila melanogaster (D-Stat) (Hou et al., 1996; Yan et al., 1996c),
Anopheles gambiae (Ag-Stat) (Barillas-Mury et al., 1999), Dictyostelium discoideum
(Dd-Stat) (Kawata et al., 1997) and Coenorhabditis Elegans (Liu et al., 1999). These Stat
proteins show highest similary with Stat3 and Stat5 of mammalian Stats. The existence of a Stat
molecule in slime mold Dictyostelium is of general interest, since it argues for the presence of
tyrosine phosphorylation also in Dictyostelium (reviewed in Darnell, 1997; Kay, 1997).
5.6.2 The domain structure of Stats
The Stats can be divided into several domains based on sequence comparison and the
three-dimensional structures of the DNA-bound dimers of the core regions of Stats 1 and 3
(Becker et al., 1998; Chen et al., 1998). The domains include an amino terminal domain,
coiled-coil, DNA-binding, linker, SH2 and transcriptional activation domain (Figure 7).
The SH2 domain is conserved in Stats and it is central to the function of Stats in
converting Stats from latent cytoplasmic proteins into their active forms. Activation of Stats
requires phosphorylation of the conserved tyrosine residue located directly on the C-terminal
side of the SH2 domain. During this process, the Stats are recruited to tyrosine phosphorylated
cytokine receptors through their SH2 domains (Greenlund et al., 1994; Stahl et al., 1995), and
following phosphorylation of the conserved tyrosine, the Stats undergo dimerization through a
reciprocal SH2-phosphotyrosine interaction (Shuai et al., 1994; Greenlund et al., 1995). Only
the Stat dimer is transcriptionally active, and Stat monomers are unable to bind DNA, and
importantly, only the dimer translocates to nucleus from the cytoplasm, where the Stats are
activated. Furthermore, during activation of Stats, the SH2 domain has been found to be
required for interaction with and subsequent phosphorylation by Jaks (Gupta et al., 1996).
Mutation of either the conserved, phosphotyrosine-binding arginine of the SH2 domain or the
conserved tyrosine following the SH2 domain abrogates Stat activity. Differences in the SH2
domains of Stats determine, at least partially, the specificity of Stat binding to various cytokine
receptors (Heim et al., 1995).
The DNA binding domain is located in the middle of Stat molecules and is highly
conserved between Stats. It forms a β-barrel with an immunoglobulin fold, showing similarity
to DNA binding domains of NF-κB and p53 (Becker et al., 1998; Chen et al., 1998). All Stats,
except for Stat2, bind to symmetrical DNA sequences called GAS, and the DNA binding
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domain determines the specificity in the recognition of DNA sequences between Stats
(Horvath et al., 1995; Ehret et al., 2001). Phosphorylated Stat2 only weakly binds DNA,
suggesting it may function only in a heterotrimeric complex with Stat1 and IRF-9 in binding to
the ISRE elements (Qureshi et al., 1995). The linker domain is critical for the correct structure
of the DNA binding domain. The highly conserved N-terminal domain has been reported to
mediate oligomerization of Stat dimers to form tetramers or higher oligomers and thus,
promote co-operativity between Stats in DNA binding (Vinkemeier et al., 1996; Xu et al.,
1996; John et al., 1999). Co-operative binding may be important, since the Stat-DNA
interaction is defined by only few contacts (Becker et al., 1998; Chen et al., 1998).
The coiled-coil domain consists of a large, four-helix bundle forming an exposed
hydrophilic area on the surface of Stats. The coiled-coil domain mediates interactions with
several regulatory proteins such as IRF9, c-Jun, PIAS, StIP1 and N-myc interacting protein
(Nmi) (Horvath et al., 1996; Zhang et al., 1999b; Zhu et al., 1999; Collum et al., 2000). This
domain is also implicated in receptor binding, tyrosine phosphorylation and nuclear export of
Stats (Begitt et al., 2000; Zhang et al., 2000a).
5.6.3 The C-terminus of Stats is involved in transcriptional activation
The C-terminus encodes a transcriptional activation domain (TAD), and it is the most
divergent part between Stats ranging from 50 to 150 amino acids in length. Stat isoforms
missing TADs have been identified, and they are defined by the Creek alphabet β, to
distinguish from the longer α isoforms. Although the β isoforms can function as dominant
negatives when overexpressed, in vivo they may promote transcription by binding with other
transcriptional coactivators (Schaefer et al., 1995; Bromberg et al., 1996; Caldenhoven et al.,
1996; Schaefer et al., 1997; Ivanov et al., 2001). The Stat3β-/- mice that have been generated
suffer from delayed recovery from endotoxin shock and show hyperresponsiveness of a set of
LPS-inducible genes in liver, indicating important functions for the Stat3β isoform in vivo
(Yoo et al., 2002).
Serine phosphorylation of the TADs of Stat 1, 3, 4 and Stat5a/b has been reported (Wen
et al., 1995; Zhang et al., 1995). In general, serine phosphorylation of Stat1, Stat3 and Stat4
increases their transcriptional potential (Wen et al., 1995). However, the effect of serine
phosphorylation on transcription varies depending on the promoter, and in some promoters
serine phosphorylation is not required and even in some cases decreased transcriptional activity
of Stat3 has been detected (Chung et al., 1997b; Kovarik et al., 2001, reviewed in Decker and
Kovarik, 2000). Phosphorylation of Ser 727 in Stat1 is required for association with MCM5, a
member of the mini-chromosome maintenance (MCM) family proteins involved in DNA
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Figure 7. Schematic domain structure of Stat transcription factors.
replication (Zhang et al., 1998). On the other hand, in the ISGF3 complex, where Stat1
heterodimerizes with Stat2, serine phosphorylation of Stat1 is not required, and the Stat1β is
able to form the transcriptionally active ISGF complex (Bromberg et al., 1996). Cytokines and
growth factors, which induce Stat tyrosine phosphorylation, induce also serine
phosphorylation, while a number of stimuli including LPS, UV and TNFα induce only Stat
serine phosphorylation. The kinases responsible for serine phosphorylation of Stats vary
depending on the stimuli, and the same stimuli can induce serine phosphorylation of distinct
Stats via different routes. To summarize somewhat controversial data, p38 has been found to
phosphorylate Stat1 in response to stress, such as UV, while it is not considered as the Stat1
kinase in IFN-γ signaling (Kovarik et al., 1999; Kovarik et al., 2001). Following growth factor
and cytokine stimulation, Stat3 is a target for ERKs, and in stressed cells JNK may be
responsible for Stat3 phosphorylation (Lim and Cao, 2001). In Src-transformed fibroblasts,
p38 and JNK inhibitors interfere with the transcriptional activity of Stat3 (Turkson et al., 1999).
In addition, serine phosphorylation of Stat6 by p38 has been reported to enhance its
transcriptional potential (Pesu et al., 2000; Pesu et al., 2002). All in all, the importance and
mechanisms of serine phosphorylation-mediated regulation of Stats are not well understood.
Co-activators found to interact with Stats to date and modulate their transcriptional
potential include Sp1 for Stat1 (Look et al., 1995), c-Jun for Stat3β (Schaefer et al., 1995), the
glucocorticoid receptor (GR) for Stat3, Stat5a and Stat5b (Stocklin et al., 1996; Zhang et al.,
1997; Cella et al., 1998), CBP and p300 for Stat1, Stat2, Stat5a, Stat5b and Stat6 (Bhattacharya
et al., 1996; Zhang et al., 1996a; Pfitzner et al., 1998; Gingras et al., 1999; McDonald and
Reich, 1999), Nmi for Stat1 and Stat5 (Zhu et al., 1999), and p100 for Stat6 (Yang et al., 2002).
5.7 Regulation of the Jak/Stat pathway
Given the central role of Jak kinases in the activation of cytokine-mediated signaling as
well as the crucial role of cytokines in determining cell fate, for example during hematopoiesis,
it is clear that mechanisms negatively regulating the Jak-initiated Stat pathway must exist
(reviewed in Yasukawa et al., 2000). Much of the research of negative regulation of the
Jak/Stat pathway was first focused on protein tyrosine phosphatases, but recently, new protein
families regulating Jak/Stat pathway have been identified, those called as protein inhibitors of
Stats, PIAS, and suppressors of cytokine signaling, SOCS, families. Some aspects of
downregulation of Jak/Stat signaling are presented in this chapter.
5.7.1 Protein tyrosine phosphatases, PTPases
Tyrosine phosphorylation is a rapid and reversible process, and thus the obvious
candidates for regulation of this phosphorylation process are protein tyrosine phosphatases
(PTPases). Regulation of both Jak kinases and Stat proteins by PTPases has been reported, but
only Jak regulation is discussed here.
The SH2-containing protein tyrosine phosphatase-1, SHP-1, has been found to
suppress the effects of EPO, IL-3, Steel factor, IFN-γ, GM-CSF and CSF-1 (Yi et al., 1993;
David et al., 1995a; Klingmuller et al., 1995; Paulson et al., 1996). SHP-1 exerts its effects by
negatively regulating Jak2. In EPO signaling, SHP-1 binds to the tyrosine-phosphorylated
28 Pipsa Saharinen
C-terminal region in the EPOR and dephosphorylates Jak2 (Klingmuller et al., 1995; Yi et al.,
1995). The importance of SHP-1 in cytokine signaling is evident from the mutant motheaten
mouse strain harbouring an inactivating mutation in SHP-1 (Shultz et al., 1993; Tsui et al.,
1993). These mice suffer from loss of hair, lymphoid and myeloid abnormalities,
immunodeficiency and autoimmune diseases. In humans, a truncated EPOR, where the binding
site for SHP-1 is missing, results in increased hematocrit levels due to enhanced EPO signaling
(de la Chapelle et al., 1993).
CD45 is a transmembrane phosphatase expressed in all hematopoietic lineages during
all stages of development. In lymphoid cells CD45 regulates T and B cell antigen receptor
signaling, mainly through Src family kinases (Alexander, 2000). Recently, CD45 was found to
negatively regulate signaling through IL-3, EPO and IFN-γ receptors as well. The
cytokine-mediated activation of JAKs and STATs is enhanced in mice lacking the cd45 gene
and in vitro, CD45 directly dephosphorylates and binds to JAK (Irie-Sasaki et al., 2001).
PTP1B is a cytoplasmic tyrosine phosphatase, which downregulates Jak2 and Tyk2
kinases by directly recognizing and dephosphorylating their A-loop sequences, which contain
the consensus substrate motif (E/D-pY-pY-R/K) of PTP1B (Myers et al., 2001). In contrast,
PTP1B does not regulate Jak1 or Jak3, whose A-loops do not fit the consensus sequence.
PTP1B-deficient mice show enhanced leptin signaling with increased tyrosine phosphorylation
of Jak2 and Stat3, but not of Jak1, indicating that that Jak2 is a physiological substrate for
PTP1B (Myers et al., 2001; Cheng et al., 2002).
While Jak2 and Tyk2 have been identified as substrates for PTP1B, the T cell PTPase
(TCPTP) specifically interacts and dephosphorylates Jak1 and Jak3 (Simoncic et al., 2002).
TCPTP-deficient mice have defects in the hematopoietic system. T cells from these mice show
increased Stat5 tyrosine phosphorylation by IL-2 stimulation, and IFN-treatment results in
elevated Stat1 and Jak1 activation. The nuclear isoform of TCPTP, TC45, was recently
identified as a nuclear PTPase responsible for dephosphorylation of Stat1 (ten Hoeve et al.,
2002).
5.7.2 SH2b-β
SH2b-β was identified as an activator of Jak2 following GH stimulation (Rui and
Carter-Su, 1999). SH2b-β belongs to a family of adapter proteins with two other members, APS
and Lnk (Huang et al., 1995; Yokouchi et al., 1997). These proteins have a C-terminal SH2
domain and more N-terminal PH domain. Upon GH stimulation SH2b-β associates through its
SH2 domain with Jak2 leading to Jak2 activation, but does not activate other Jak kinases
(O’Brien et al., 2001). On the other hand, APS inhibits Jak2 following GH stimulation, and can
also inhibit Jak1. Both APS and SH2b-β bind to Jak1, Jak2 and Jak3 despite their differential
effect on kinase activity, and may function as adapter proteins for Jaks.
5.7.3 Protein inhibitors of Stats, PIAS
The mammalian PIAS family consists of six members, PIAS1, PIAS3, PIASy, PIASxα
and PIASxβ, and GBP (Valdez et al., 1997, reviewed in Shuai, 2000). PIAS1 was identified as
a Stat-interacting protein in a yeast two-hybrid screen (Liu et al., 1998). PIAS1 and PIAS3
inhibit DNA binding of Stat1 and Stat3, respectively, and thereby Stat-mediated transcription
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(Chung et al., 1997a; Liu et al., 1998). PIAS-mediated inhibition has been reported to be
regulated by methylation of Stats, which was found to inhibit PIAS from binding to Stats, thus
increasing the DNA binding ability of Stats (Mowen et al., 2001). Interestingly, reduced
methylation in certain malignancies may explain their unresponsiveness to IFN-γ treatment
(Mowen et al., 2001). PIASy suppresses Stat1-mediated transcription in IFNγ signaling, but
does not affect Stat DNA binding, thus acting as a transcriptional co-repressor (Liu et al.,
2001). In agreement with the negative regulation of Stats by PIAS proteins in mammals, the
Drosophila PIAS homolog dPIAS has been found to negatively regulate Stat92E (D-Stat) in
the fly (Betz et al., 2001). The PIAS proteins have been reported to function as SUMO E3
ligases (Kahyo et al., 2001; Kotaja et al., 2002), but the possible sumoylation of Stats remains
to be resolved.
5.7.4 The suppressors of cytokine signaling, the SOCS family
In contrast to the constitutively expressed phosphatases, the SOCS proteins are induced
by a number of cytokines, summarized in table 3. The SOCS proteins are found in most
hematopoietic tissues but the expression pattern varies between SOCS family members. Since
the SOCS proteins negatively regulate cytokine signaling, they act as classical negative
feedback regulators. The SOCS proteins are characterized by an N-terminal, relatively
divergent region followed by a SH2 domain and a C-terminal SOCS box homology region. The
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SOCS protein Induced by Action
CIS
IL-1, IL-6, IL-12, IL-13, LIF, G-CSF, GM-CSF,
TPO, IFN-γ, IL-2, IL-3, GH, leptin, PRL, EPO,
LPS, TSLP, CNTF
Suppresses EPO, IL-3, IL-2, GH and PRL
signaling
SOCS-1
IL-2, IL-3, IL-6, IL-13, EPO, GH, PRL, GM-CSF,
thyropropin, CNTF
Suppresses IFN-γ, IFN-α, IL-2, IL-3, EPO,
IL-4, IL-6, LIF, GH, PRL, TNF-α, TSLP
signaling
SOCS-2
IL-1, IL-2, IL-3, IL-4, IL-6, G-CSF, GM-CSF,
EPO, IL-9, GH, PRL, IFN-γ, CNTF, IL-10
Partial suppression of GH, IL-6, LIF and IGF-1
signaling
SOCS-3
IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-12, IL-13,
M-CSF, G-CSF, EPO, TPO, TNF-α, LIF, IL-1β,
IL-9, IL-10, IL-11, GH, leptin, PRL, GM-CSF,
LPS, insulin, CNTF, thyropropin
Suppresses EPO, IL-2, IL-3, IL-4, IL-6, IL-9
IL-11, LIF, IFN-γ, GH, PRL, leptin, insulin and
IGF-1 signaling
SOCS-4 Unknown Unknown
SOCS-5 Unknown Partial suppression of IL-6 and LIF signaling
SOCS-6 Unknown Unknown
SOCS-7 Unknown Binds to Nck
Table 3. SOCS proteins in cytokine signaling, modified from (Greenhalgh and Hilton, 2001).
SOCS proteins regulate both Jaks and Stats, and despite conserved domain structure, the
mechanisms utilized by the SOCS proteins in regulating cytokine signaling differ (reviewed in
Greenhalgh and Hilton, 2001; Krebs and Hilton, 2001).
The first identified inhibitor, CIS (cytokine-inducible Src homology -2 containing
protein), was cloned as an immediate early gene induced by IL-2, IL-3 and EPO (Yoshimura et
al., 1995). CIS binds phosphotyrosine residues in the EPOR and IL-3Rβc, and prevents
activation of Stat5, possibly by sequestering phosphotyrosine motifs required for Stat5
association.
Certain other members of the SOCS family, bind directly to Jak kinases. SOCS-1 (JAB
or SSI-1) can bind all Jak kinases, and inhibit their activity (Endo et al., 1997; Naka et al., 1997;
Starr et al., 1997). The SH2 domain of SOCS-1 has been shown to interact with Y1007 in the
A-loop of Jak2, in a phosphorylation-dependent manner (Yasukawa et al., 1999). It has been
suggested that SOCS-1 inhibits Jak activity through its kinase inhibitory region, which
presumably interacts with the catalytic cleft of Jak kinase domains (Yasukawa et al., 1999).
The kinase inhibitory region possesses sequence similarity to the A-loop double tyrosine
motifs of Jaks, and it is suggested to mimic the activation loop by acting as a pseudosubstrate
inhibitor for Jaks. In addition, SOCS-1 has been found to inhibit Tec, a member of the Tec/Btk
family of non-receptor tyrosine kinases (Ohya et al., 1997).
Eight SOCS proteins have been cloned today (CIS and SOCS1-7). Database searches
have revealed a variety of cellular proteins containing the SOCS box, which are not otherwise
related to SOCS family, and have not been found to regulate cytokine signaling (Hilton et al.,
1998). These proteins can be grouped by domains located in the N-terminal regions: WD-40
repeats (WSB-1 and –2), ankyrin repeats (ASB-1-9), SPRY (SSB-1-3), and small GTPase
domains. A possible function for the SOCS box in these proteins comes from interaction
studies, where the SOCS box has been found to interact with elongin B and elongin C, which
are components of the ubiquitin proteasome pathway (Kamura et al., 1998; Zhang et al.,
1999a). This interaction has been suggested to regulate the activity of SOCS proteins, or SOCS
binding proteins, by directing them to degradation. Evidence for degradation-based regulation
is emerging also in cytokine signaling. In GHR signaling, inhibition by CIS involves an active
proteosomal pathway (Ram and Waxman, 2000), and the active, tyrosine phosphorylated Jak2
was recently found to be regulated by the ubiquitin-proteasome pathway in a
SOCS-1-dependent manner (Ungureanu et al., 2002). Thus, SOCS-mediated negative
regulation may involve two steps: first, SOCS proteins inhibit signaling by binding to active
signaling complexes, and second, SOCS bound signaling components are targeted to
degradation via SOCS proteins (reviewed in Kile et al., 2002).
The complex network of cytokines and their multiple effects on various cell types have
been partly suggested to depend on SOCS proteins. The SOCS proteins are believed to mediate
crosstalk inhibition between cytokine signaling pathways. For example, IL-10 attenuates a
variety of inflammatory responses in immune cells, and has negative effects on IFN signaling.
IL-10 induces expression of SOCS-3, which is supposed to inhibit INF-γ-induced Stat1
activation and gene expression in monocytes (Ito et al., 1999).
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While inhibiting the Jak/Stat pathway, SOCS-3 has been found to sustain activation of
the Ras pathway (Cacalano et al., 2001). Tyrosine phosphorylation of SOCS-3, which has been
found to occur following cytokine and growth factor stimulation, results in interaction of
SOCS-3 with RasGAP and sustained ERK activity (Cohney et al., 1999; Cacalano et al., 2001).
5.8 Biological role of the Jak/Stat pathway
In cytokine signaling, one cytokine can often induce the activation of more than one Jak
kinase, and in addition, activate tyrosine kinases other than Jaks as well. Therefore, it has been
difficult to find out, which of these kinases have unique or redundant roles in cytokine
signaling. To clarify the in vivo function of the Jak/Stat pathway, mice lacking individual Jak
and Stat family members have been generated, as well as a double knockout of Stat5a and
Stat5b (reviewed in Leonard and O’Shea, 1998). These mice demonstrate nonredundant
functions for Jaks and Stats in cytokine signaling. In addition, analysis of hematopoietic
disorders and malignancies have revealed biological processes involving the Jak/Stat pathway.
5.8.1 Jak deficiency
Jak1-deficient mice show perinatal lethality (Rodig et al., 1998). They are small at birth
and fail to nurse. Lymphopoiesis, but not myelopoiesis, is impaired with reduced numbers of T
and B lymphocytes, and Jak1-deficient cells fail to respond to IFNs, γc utilizing cytokines (IL-2,
IL-4, IL-7, IL-9, IL-15) and cytokines using gp130 or gp130 like protein (IL-6, LIF, CT-1,
CNTF, OSM, IL-11). The cause for the perinatal death is suggested to result from a neuronal
defect; neurons from Jak1 deficient mice do not respond to LIF, CT-1 and CNTF, and die
apoptotically.
Jak2-deficient mice are embryonically lethal, and die at embryonic day 12.5, due to
absence of definitive erythropoiesis (Neubauer et al., 1998; Parganas et al., 1998). The
similarities in phenotypes between mice deficient in Jak2, EPO or EPOR suggest a specific role
for Jak2 in EPO signaling. Jak2-deficient fetal liver myeloid progenitors fail to respond to EPO,
TPO and βc utilizing cytokines (IL-3, IL-5, GM-CSF), while Jak2-deficient fibroblasts are
unresponsive to IFN-γ.
Jak3-deficient mice exhibit phenotypes indistinguishable from those of γc-deficient
mice in having severely impaired T and B cell development (Nosaka et al., 1995; Park et al.,
1995; Thomis et al., 1995), since signaling through γc-containing receptors is missing. These
mice have smaller thymi, spleens and lymph nodes as compared to wild-type mice. They have
defective B cell development and reduced numbers of thymocytes, and the residual T cells are
functionally deficient. Mutations in Jak3 have been characterized in humans, and these patients
suffer from severe combined immunodeficiency, SCID, with complete absence of
T-lymphocytes and non-functional B-lymphocytes (Macchi et al., 1995; Russell et al., 1995).
The phenotype of Jak3-SCID is very similar to the X-linked severe combined
immunodeficiency (X-SCID) resulting from mutations in γc (reviewed in Leonard, 1996).
Thus, Jak3 has an essential role in γc-dependent lymphoid development. At least 27 unique
mutations affecting all JH domains have been characterized in Jak3, resulting in SCID, and the
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mutations have been collected in a Jak3 database (http://www.uta.fi/Imt/bioinfo/Jak3base/)
(Notarangelo et al., 2001). These mutations have been especially interesting in aiming to
understand the function and regulation of Jak3 by its JH domains (described in Discussion).
Tyk2-deficient mice do not show any obvious abnormalities or any difference with
regard to lymphoid, monocyte, or myeloid cell development when compared to wild-type mice,
but show impaired innate and adaptive immunological responses (Karaghiosoff et al., 2000;
Shimoda et al., 2000). For example, IFN-α + LPS fail to induce nitric oxide (NO) production in
peritoneal macrophages of Tyk2-deficient mouse, and the Tyk2-/- mice show selective
susceptibility to viruses. Tyk2-/- mice were found to have clear, but reduced responses to type I
IFNs, indicating a redundant role for Tyk2 in the activation of cytokine receptor signaling and
suggesting a role for Tyk2 as an amplifier of cytokine signaling. This was surprising, since
Tyk2 was originally cloned as an essential kinase for IFNα signaling using cell lines defective
in type I IFN responses, and, for example, Jak1 deficiency results in total lack of type I IFN
responses in mice (Velazquez et al., 1992). This is also different from the previously found
obligatory roles of other Jak kinases in cytokine receptors. It is possible that Tyk2 has a
different role in mice and in humans, which might explain the different results from knockout
mice and human cell lines. Tyk2 deficiency resulted also in impaired IFN-γ responses in mice,
although Tyk2 is not activated by IFN-γ. This may be explained by reduced levels of Stat1
protein expression in Tyk2-/- mice compared to wild-type mice. Tyk2 was found to be required
for IL-12-induced IFN-γ production by T cells, and thus for TH1 differentiation, while having a
redundant role in IL-12-induced T cell proliferation. A selective, essential role for Tyk2 was
found in type I IFN- and IL-12-induced activation of Stat3, which, however, is not considered
essential for the major biological functions of these cytokines.
5.8.2 Stat deficiency
Stat1-deficient mice show increased susceptibility to infection by viruses and microbial
pathogens (Durbin et al., 1996; Meraz et al., 1996). Although Stat1 is activated by a number of
cytokines in cell lines, the major defect in Stat1-deficient mice is in IFN-α and IFN-γ signaling.
Thus, Stat1 is primarily, if not entirely, important for signaling by IFNs. Recently, a L706S
substitution in the Stat1 gene was reported from a patient, who suffered from a mycobacterial
disease (Dupuis et al., 2001). The Stat1 mutation was found to interfere with tyrosine
phosphorylation of Stat1 resulting in impaired IFN-γ signaling. Stat2-deficient mice are
primarily defective in signaling by type I IFNs, and are sensitive to viral infections (Park et al.,
2000).
The targeted disruption of the Stat3 gene in mice has been found to result in embryonic
lethality, at embryonic day 6.5-7.5 (Takeda et al., 1997). Stat3 has been found essential for
maintaining the undifferentiated state of embryonic stem (ES) cells, but the function of Stat3 in
early embryonic development remains unresolved (Matsuda et al., 1999; Raz et al., 1999).
Using a Stat3 conditional knockout approach, Stat3 was found to be essential for IL-6-induced
suppression of apoptosis of T cells (Takeda et al., 1998), and IL-2-induced T cell proliferation
by regulating expression of IL-2Rα (Akaishi et al., 1998, reviewed in Akira, 2000; Levy and
Lee, 2002). In macrophages Stat3 was found to be required for IL-10-mediated
anti-inflammatory responses (Takeda et al., 1999). The in vitro motility of epidermal cells
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lacking Stat3 was impaired affecting, for example, wound healing in the Stat3-/- mice (Sano et
al., 1999). In mammary gland, Stat3 is specifically activated at the start of involution. In the
Stat3-/- mice, the apoptosis of mammary epithelial cells was decreased and involution delayed
(Chapman et al., 1999). Stat3 deficiency in the brain resulted in perinatal lethality due to
neuronal defects (Alonzi et al., 2001). In liver, Stat3 was required for the acute phase response
by IL-6, in accordance with the identification of Stat3 first as a factor binding to the acute phase
response DNA element (Akira et al., 1994; Lutticken et al., 1994; Raz et al., 1994; Zhong et al.,
1994b). In conclusion, many of the functions of Stat3 are linked to signaling through gp130.
Mice lacking Stat4 show a differentiation defect of TH1 cells and enhanced
differentiation towards TH2 phenotype, due to defective IL-12 signaling (Kaplan et al., 1996b;
Thierfelder et al., 1996). NK cells and T cells from these mice are unresponsive to IL-12. Thus,
the effects of Stat4 are restricted to IL-12 signaling, in accordance with the findings that Stat4 is
activated only by IL-12.
Stat5a-deficient mice show impaired lactation and lobuloalveolar proliferation of the
mammary epithelium during pregnancy, indicating defective prolactin signaling (Teglund et
al., 1998). Bone marrow-derived macrophages from these mice exhibit defective
GM-CSF-induced proliferation and gene expression. In contrast, Stat5b-deficient mice are
impaired in GH signaling showing reduced body weight and loss of sexually dimorphic growth
(Udy et al., 1997). Analysis of the immune systems of Stat5a- and Stat5b-deficient mice
suggests a role for both Stat5 proteins in signaling by IL-2. Stat5a was found to mediate its
effects through maintaining the expression of IL-2Rα required for formation of the high
affinity IL-2R. Stat5b-deficient mice showed impaired IL-2 signaling, which was not totally
due to reduced level of the high affinity IL-2 receptor. Both of these mice showed a defect in
NK cell development. Stat5a/5b double knockout mice do not have NK cells and show
impaired T cell proliferation, due to loss of induction of cyclin D2, cyclin D3 and cdk6. Female
mice lacking functional Stat5a and Stat5b are infertile (Teglund et al., 1998; Moriggl et al.,
1999). Stat5a/5b knockout mice show fetal anemia due to impaired BclXL expression induced
by EPO (Socolovsky et al., 1999).
Stat6-deficient mice are defective in TH1 differentiation, differentiation being biased
towards TH2 cells. The lymphoid cells from these mice do not respond to IL-4 or IL-13, and
exhibit impaired IgE class switch (Takeda et al., 1996aKaplan et al., 1996a; Shimoda et al.,
1996; Takeda et al., 1996b).
5.8.3 SOCS-deficient mice
The SOCS proteins are strongly linked to cytokine signaling and Jak/Stat pathway, and
thus, the results obtained from mice deficient in SOCS-1, -2, -3 and CIS that have been
generated, require consideration.
SOCS-1-deficient mice die at three weeks of age showing fatty degeneration of the
liver, monocytic infiltration of organs, and lymphopaenia (Marine et al., 1999b). The SOCS-1-/-
phenotype is reminiscent of that induced by elevated IFN-γ levels in neonatal mice, and the
SOCS-1-/- phenotype can be corrected by inactivating anti-IFN-γ antibodies or by crossing with
IFN-γ-/- mice. Reconstitution of irradiated Jak3-/- mice with SOCS-1-/- bone marrow confers the
lethal SOCS-1-/- phenotype, indicating an important role for lymphocytes in the SOCS-1-/-
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phenotype. Also, crossing SOCS-1-deficient mice with RAG2-/- mice rescues the SOCS-1-/-
phenotype. These results support the model that SOCS-1 negatively controls IFN-γ signaling,
but it may also have a role in signaling through other cytokine receptors.
The SOCS-2-deficient mice, especially males, grow significantly larger than their wild
type counterparts, with a 40% increase in size by 12 weeks of age (Metcalf et al., 2000). This
suggests hyperresponsive GH signaling in SOCS-2-deficient mice. SOCS-3-/- mice die
between embryonic days 12 and 14 due to increased erythrocytosis surrounding the fetal liver
and abdominal region, whereas over-expression of SOCS-3 blocks fetal liver hematopoiesis
(Marine et al., 1999a). CIS-deficient mice show no abnormal phenotype (Marine et al., 1999a).
Transgenic animals over-expressing CIS have phenotypes similar to those resulting from
Stat5a and Stat5b deficiency, suggesting that CIS negatively regulates Stat5 function in
growth, mammary gland function and T cell development (Matsumoto et al., 1999).
5.8.4 Jak/Stat pathway in oncogenesis
In contrast to normal signaling, where activation of Jaks and Stats is rapid yet transient,
constitutive Jak/Stat signaling has been associated with malignant processes. Constitutive Jak
and Stat activation has been detected in a number of transformed cells, induced either by
viruses, such as HTLV-1, v-Abl and Epstein-Barr virus or by oncogene activation, such as Src
(Table 4) (Danial et al., 1995; Migone et al., 1995; Yu et al., 1995; Campbell et al., 1997;
Garcia et al., 1997). In addition, constitutive Stat activation (Stat1, Stat3 and Stat5) has been
detected in a number of primary tumors, such as breast cancer, lung cancer, prostate cancer,
head and neck tumors, brain tumors, multiple myeloma, leukemias, lymphomas, renal cell
carcinoma, melanoma, pancreatic cancer and ovarian cancer (reviewed in Bowman et al.,
2000; Bromberg, 2002).
There is growing evidence for direct participation of Stats in oncogenesis (Turkson et
al., 1998; Bromberg et al., 1999). In one study, the dominant negative form of Stat3, Stat3β,
was able to prevent Src-induced transformation of NIH3T3 cells, while it did not prevent Ras-
induced transformation (Turkson et al., 1998). In another study, ectopic expression of a
genetically modified Stat3 capable for dimerization and DNA binding in the absence of
tyrosine phosphorylation, induced transformation of NIH 3T3 fibroblasts (Bromberg et al.,
1999). This result demonstrated that the activated Stat3 is an oncogene, and that Stat3-driven
gene transcription is sufficient to induce at least certain features of cell transformation in the
absence of tyrosine kinase signaling (Bromberg et al., 1999). The Stat3 target genes with a role
in controlling cell proliferation and survival include Bcl-xl, Mcl-1, Bcl-2, cyclin D1, c-Myc,
p21 WAF1/CIP1 and VEGF (Bromberg et al., 1999; Catlett-Falcone et al., 1999; Sinibaldi et al.,
2000; Bowman et al., 2001; Epling-Burnette et al., 2001; Niu et al., 2002).
In addition to tyrosine phosphorylation, constitutive serine phosphorylation of Stat1
and Stat3 has been detected in human tumors (Frank et al., 1997). Serine phosphorylation
seems to have a role in transformation, since the S727A mutant Stat3 can prevent Src-induced
transformation, and so can inhibition of the p38 serine kinase, which phosphorylates Stat3
(Bromberg et al., 1998b; Turkson et al., 1999).
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Although Stat1 has been found activated in transformed cells, it unlikely contributes to
oncogenesis. Instead, Stat1 has been found growth inhibitory, the apoptosis and growth arrest
being mediated by induction of caspases and the cdk inhibitor p21WAF1/CIP1 (Bromberg et al.,
1996; Chin et al., 1996; Kumar et al., 1997; Bromberg et al., 1998a; Grimley et al., 1998; Xu et
al., 1998). Stat1 also cooperates with the tumor suppressor BRCA1 in induction of certain
IFN-γ-inducible genes, such as p21WAF1/CIP1 (Ouchi et al., 2000). Furthermore, Stat1-deficient
mice gain tumors more frequently than their wild-type counterparts and Stat1 deficiency
increases tumor development in p53 -/- mice, suggesting a role for Stat1 as a tumor suppressor
(Kaplan et al., 1998).
Constitutive Jak activation has also been detected in certain malignancies. Jak3 is
activated in Sezary’s syndrome, and in human acute lymphocytic leukemia (ALL) Jak2 is
directly involved in the malignant process (Zhang et al., 1996b; Lacronique et al., 1997; Ho et
al., 1999). In ALL, translocation of the short arm of chromosome 9, containing the kinase or the
double kinase domain of Jak2, to the short arm of chromosome 12, containing the
oligomerization domain of the TEL transcription factor, results in a constitutively active
TEL-Jak2 fusion protein (Lacronique et al., 1997; Ho et al., 1999). Dimerization of the two
Jak2 JH1 domains through the TEL fusion partner mimics cytokine-induced activation of Jak2.
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Cell type Oncogene Activated Stats
Fibroblasts v-Src Stat3
c-Src Stat3
v-Fps (Fes) Stat3
v-Sis (PDGF) Stat3
Polyoma virus middle T antigen Stat3
v-Ras -
v-Raf -
v-Ros Stat3
IGF-1 receptor Stat3
c-Eyk, v-Eyk Stat1, Stat3
Myeloid v-Src Stat1, Stat3, Stat5
v-Fgr -
T-cell Lck Stat3, Stat5
Mammary/lung epithelial v-Src Stat3
Etk/Bmx Stat1, Stat3, Stat5
Gallbladder adenocarcinoma v-Src Stat3
Pre-B lymphocytes v-Abl Stat1, Stat5
Erythroleukemia/blast
cells/basophils/mast cells
BCR-Abl Stat1, Stat5
Primary bone marrow BCR-Abl Stat5
Table 4. Stat activation by oncogenes (modified from Bowman et al., 2000).
TEL-Jak2, when introduced in a hematopoietic cell line, confers these cells factor-independent
growth, which is dependent on TEL-Jak2-induced constitutive Stat5 activation (Schwaller et
al., 1998). The AG490 inhibitor of Jak2 can inhibit the leukaemia cells containing hyperactive
TEL-Jak2, and also many other tumor-derived cell lines, suggesting that Jak2 is critical in
many cancers (Meydan et al., 1996; Turkson and Jove, 2000).
The SOCS proteins are important negative regulators of the Jak/Stat pathway. It has
been discovered that in hepatocellular carcinomas (HCC) SOCS-1 levels are reduced due to
abnormal methylation of the SOCS-1 gene leading to transcriptional silencing (Yoshikawa et
al., 2001). IL-6-driven Jak/Stat signaling is constitutive in HCC cell lines and primary HCCs,
and can be inhibited by introducing SOCS-1 into these cells, or by inhibiting Jak2 activity with
AG490 (Kishimoto and Kikutani, 2001; Yoshikawa et al., 2001). Thus, SOCS-1 may be a
tumor suppressor protein.
The first evidence for constitutive Jak/Stat activation in oncogenesis came from studies
of Drosophila fruit fly. In Drosophila, the unpaired gene (upd) was found to encode a ligand
that activates the Drosophila Jak/Stat pahway through the receptor mom (master of marelle),
which is related to mammalian cytokine receptors, especially gp130 (Harrison et al., 1998;
Chen et al., 2002). Lethal gain-of-function mutations, resulting in hyperactivation of the
Drosophila Jak, Hop (hopscotch), were characterized and found to result in hematopoietic
neoplasia resembling leukemia (Harrison et al., 1995; Luo et al., 1997). Dominant suppressors
of this phenotype map to loss-of-function mutations in the Drosophila Stat (D-Stat) gene
(marelle, stat92E) (Yan et al., 1996bYan et al., 1996b).
5.9 Other signaling pathways initiated by cytokines
In addition to the Jak/Stat pathway, a number of other signaling pathways are activated
by cytokine receptors (Figure 8), including the Ras and PI3K pathways, as well as pathways
involving tyrosine kinases from the Src and Tec/Btk families and protein kinase C family of
serine/threonine kinases. However, Jaks have been found essential for activation of virtually all
of the downstream signaling pathways initiating from cytokine receptors (Miura et al., 1994a;
Miura et al., 1994b; Stancato et al., 1997; Sakatsume et al., 1998). One important function of
Jak kinases, in addition to Stat activation, is the phosphorylation of the cytokine receptor itself.
The phosphorylated tyrosines in the receptor serve as binding sites for many signaling proteins
facilitating their activation, and progression of signaling downstream of the receptor.
Jaks have been also found to directly participate in signaling pathways other than Stats.
For example, Jak3 and Jak2 induce activation of Pyk2 through IL-2R and IFN-γR, respectively
(Miyazaki et al., 1998; Takaoka et al., 1999). Activation of insulin receptor substrates IRS-1
and IRS-2 by IL-2, and subsequent activation of PI3-kinase, may depend on Jak1 and Jak3 (Yin
et al., 1994; Johnston et al., 1995b). Jak2 is found in a complex with adapter proteins Grb2 and
Shc, as well as nucleotide exchange factor SOS, which may activate Ras (Chauhan et al., 1995;
He et al., 1995; Wang et al., 1995; Giordano et al., 1997). Jak1 and Jak2 have been found to
interact with and phosphorylate Raf-1 leading to Raf-1 activation, and subsequent activation of
the MAPK pathway (Winston and Hunter, 1995; Xia et al., 1996; Stancato et al., 1997;
Sakatsume et al., 1998). Activation of the MAPK pathway is required for transcriptional
regulation of cytokine-inducible genes, and ERK kinases, as well as p38 and JNK have been
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implicated in serine phosphorylation of Stat1, Stat3 and Stat6 (David et al., 1995b, reviewed in
Decker and Kovarik, 2000). Jak2 has been found to associate with Vav thereby possibly linking
cytokine receptors to activation of the Rho family GTPases (Matsuguchi et al., 1995). Jak1 and
Jak2 have been implicated in IL-6 -induced activation of Btk and Tec, which also activate Rho
proteins (Takahashi-Tezuka et al., 1997).
There is also evidence that activation of Stats can occur independently of Jak kinases.
CD40 engagement has been found to induce activation of Stat6, and BCR cross-linking has
been found to induce activation of Stat5, but in both cases without detectable Jak activation
(Karras et al., 1996; Karras et al., 1997). In IL-3 signaling Src has been found to activate Stat3
(Chaturvedi et al., 1998). These data and the results from oncogene-mediated Stat activation
suggest that other tyrosine kinases than Jaks are also involved in activation of Stats.
5.9.1 Btk/Tec tyrosine kinase family
The Btk/Tec family of non-receptor tyrosine kinases includes five members, Tec,
Btk/Atk, Itk/Emt/Tsk, Bmx/Etk, and Txk, which are characterized by the presence of a
N-terminal PH domain, followed by TH, SH3, SH2 and tyrosine kinase domains (Figure 4).
However, Txk does not contain PH and TH domains, and Bmx has a relatively poorly
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Figure 8. Schematic presentation of signaling proteins and activated pathways implicated in EPOR
signaling (for references see reviews Klingmuller, 1997; Wojchowski et al., 1999, and references therein).
conserved SH3 domain, and the proline-rich region in the TH domain is missing from Bmx.
The Btk/Tec kinases are linked to a variety of different cellular processes, such as apoptosis,
cell growth, differentiation and migration (reviewed in Qiu and Kung, 2000).
The Btk/Tec family kinases are predominantly expressed in cells of hematopoietic
origin. Btk is expressed in B-lymphoid and myeloid lineages, and has a critical role in B-cell
development. Mutations in Btk lead to immunodeficiency in human, called X-linked
agammaglobulinemia (XLA), characterized by virtual absence of B-lymphocytes and plasma
cells, and consequently, immunoglobulins (Tsukada et al., 1993, reviewed in Mattsson et al.,
1996). In mice, Btk mutations also lead to B-cell defects with a milder immunodeficiency
disease (Xid) than in humans (Thomas et al., 1993; Kerner et al., 1995; Khan et al., 1995). Itk is
expressed predominantly in cells of T lymphoid lineage, and lack of Itk in mice results in the
absence of mature thymocytes and defective signaling through the T cell receptor (Liao and
Littman, 1995). Tec was originally characterized from hepatocarcinoma cells, but is also
expressed in hematopoietic cells, and Txk is expressed in myeloid and T cells (Mano et al.,
1993; Qiu and Kung, 2000). Bmx (Bone Marrow tyrosine kinase gene in chromosome X) was
identified in a bone marrow derived library, and later in prostate cancer cells (Tamagnone et al.,
1994; Robinson et al., 1996). Bmx is expressed more widely than the other family members,
including expression in cells of the myeloid lineage, in the endothelial cells of large arteries as
well as in epithelial cells (Kaukonen et al., 1996; Ekman et al., 1997; Weil et al., 1997;
Bagheri-Yarmand et al., 2001; Rajantie et al., 2001).
The Btk/Tec kinases are involved in signaling through a large number of different
transmembrane receptors, such as growth factor receptors, cytokine receptors, G-protein
coupled receptors, antigen receptors and integrins. For example, Btk is activated through mast
cell FcεR (Kawakami et al., 1994; Hata et al., 1998), BCR (Aoki et al., 1994; de Weers et al.,
1994), IL-5R (Sato et al., 1994) and gp130 (Matsuda et al., 1995), Tec through gp130 (Matsuda
et al., 1995), c-kit (Tang et al., 1994) and IL-3R (Mano et al., 1995), and Itk through CD28
(August et al., 1994), mast cell FcεR (Kawakami et al., 1995) and TCR (Gibson et al., 1996). In
addition, the Btk PH domain binds Gαq both in vivo and in vitro and this leads to Btk activation
(Bence et al., 1997). By the time the current work was initiated, no receptor was known to
activate the Bmx kinase.
The presence of at least four protein interaction domains in Btk/Tec kinases enables
these kinases to participate in multiple different signaling complexes. The PH domain has a
central role in Btk/Tec kinases, by mediating multiple protein-protein interactions. The PH
domain has been found to interact with Gq proteins (Bence et al., 1997), various protein kinase
C isoforms (Yao et al., 1994; Kawakami et al., 1995; Yao et al., 1997), F-actin (Yao et al.,
1999) and FAK (Chen et al., 2001), and in some cases the interaction results in increased
activity of the kinase.
The PH domain also binds phospholipids. The Btk PH domain preferentially binds
phosphorylation products of PI3 kinase, such as phosphatidylinositol-3,4,5-triphosphate
(PtdIns-3,4,5-P3) (Rameh et al., 1997). Mutations in the Btk PH domain have been
characterized that disrupt lipid binding by the PH domain and result in XLA or Xid (Rameh et
al., 1997; Vihinen et al., 1998). In addition to Btk, PI3K can activate also other Btk/Tec
kinases, except for Txk (Scharenberg et al., 1998; Tomlinson et al., 1999; Ekman et al., 2000).
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The Tec/Btk kinases are recruited to the plasma membrane, where they bind newly formed
PtdIns-3,4,5-P3, and become activated. The importance of PI3K mediated activation of
Tec/Btk kinases is strengthened by the finding that the p85α knockout mice have very similar
phenotype as the Xid mice (Fruman et al., 1999; Suzuki et al., 1999).
Several non-receptor tyrosine kinases have been found to regulate Btk/Tec kinases. Src
kinases have been found to phosphorylate a conserved tyrosine residue in the kinase domains of
Btk, Itk and Bmx (Y551 in Btk and Y566 in Bmx) (Mahajan et al., 1995; Park et al., 1996a;
Rawlings et al., 1996; August et al., 1997; Tsai et al., 2000), resulting in increased activity of
these kinases, and subsequent phosphorylation in the SH3 domain. The Itk TH domain can
interact with its own SH3 domain, suggesting intramolecular inhibition of kinase activity by
these domains (Andreotti et al., 1997), and phosphorylation in the SH3 domain may disrupt the
interaction leading to kinase activation. Thus, activation of Btk/Tec kinases involves two steps:
first, membrane localization through the PH domain, and second, autophosphorylation induced
by Src-mediated phosphorylation. In addition to Src kinases, also Jak kinases have been
implicated in regulation of Btk/Tec kinases. Btk and Tec associate with the IL-6R through
Jak1, which also directly phosphorylates Btk (Takahashi-Tezuka et al., 1997).
At the beginning of this work, only few substrates were known for the Tec/Btk kinases,
and no substrates had been characterized for Bmx. Btk was known to activate PLC-γ in BCR
signaling (Takata and Kurosaki, 1996), leading to increase in intracellular calcium levels.
Currently, the number of substrates has increased and now includes PKCβ1, TFII-I and the
Wiskott-Aldrich protein (WASP) for Btk, Sab, a negative regulator of Btk, and Dok-1, vav,
BRDG1, Akt and PI3K for Tec (references in Qiu and Kung, 2000).
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6 AIMS OF THE PRESENT STUDY
The Jak tyrosine kinases and their best-known substrates, Stat transcription factors,
were cloned in the beginning of the 1990s. Thereafter, an enormous amount of work has been
done to understand the mechanisms utilized by the Jak-Stat pathway in mediating signaling
from a vast number of cytokine receptors, as well as the biological role of this signaling
pathway.
The aim of the current work has been to learn about the molecular mechanisms
regulating immediate signaling events following cytokine binding to its cognate receptor. A
critical event regulating cytokine signaling is activation of Jak kinases in cytokine receptors,
and the regulation of Jak activity has been a major question in this study. The understanding of
the mechanisms regulating Jak activation in Jak-receptor complexes as well as regulation of
Stat activity may result in clinical applications in the form of new therapeutics targeted to
modulate cytokine signaling.
The specific questions to be answered in this thesis study were:
1) How is the activity of the Jak2 tyrosine kinase regulated? What is the
function of the different JH domains in regulation of Jak2?
2) What is the role of the JH2 domain in regulation of the Jak3 tyrosine
kinase? What is the role of the JH2 domain in signaling through cytokine
receptors?
3) How does the JH2 domain regulate Jak2? Can inhibitory regions be
defined within the JH2 domain?
4) How is Stat signaling regulated? Are there kinases other than Jaks that
can activate Stat proteins?
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7 MATERIALS AND METHODS
7.0.1 Cell lines
Mammalian cell culturing was carried out in the medium mentioned in table 5,
supplemented with 100U/ml penicillin and 50 µg/ml streptomycin. Before cytokine treatment, the
cells were starved in serum-free medium. Stimulation of the cells with cytokines was carried out in
serum-free medium. Insect cells were cultivated in a suspension culture at 28°C, and plated on cell
culture dishes for experiments. Infections were carried on for 72 hours followed by cell lysis.
7.0.2 Antibodies and cytokines
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Name Description Used in Culture medium
COS-7
African green monkey kidney epithelial cells, SV40
transformed, ATCC CRL-1651
I, II, IV D-MEM + 10%FBS
293 Human kidney epithelial cells, ATCC CRL-1573 II D-MEM + 10%FBS
293T
Human kidney epithelial cells, expressing the
transforming gene of adenovirus 5, ATCC CRL-1573
I, II, III, IV D-MEM + 10%FBS
γ2A
HT-1080, human fibrosarcoma cell line, ATCC CCL-121,
derived Jak2 negative cell line, resistant to antibiotic
geneticin (described in Watling et al., 1993)
I, II, III D-MEM + 10%FBS + G418
Sf-9 Insect cells (Smith et al., 1985) IV Sf900 (Invitrogen) +10%FBS
Table 5. The cell lines used with their ATCC (American Type Culture Collection, Manassas, VA, USA)
identification numbers.
Name Description Reference or source Used in
IL-2 human IL-2 R&D Systems II
IFN-γ human recombinant IFN-γ R&D Systems I, II, III
Anti-Jak2 polyclonal Silvennoinen et al., 1993c I, II, IV
Anti-Jak1 monoclonal Transduction Laboratories IV
Anti-Jak3 polyclonal Witthuhn et al., 1994 II
Anti-Stat1 monoclonal, anti-Stat1(p91) Transduction Laboratories IV
Anti-Stat1
monoclonal,
anti-ISGF-3(p91)
Transduction Laboratories IV
Anti-Stat3 monoclonal Transduction Laboratories IV
Anti-Stat5 polyclonal Santa Crutz Biotechnology IV
Anti-Stat5 monoclonal, ST5a-2H2 Zymed Laboratories I, II, III
Anti-HA monoclonal ,12CA5/16B12 Berkeley Antibody Company /Covance I, II ,III, IV
Anti-Phosphotyrosine monoclonal, 4G10 Upstate Biotechnology I, II, III, IV
Table 6. Antibodies and cytokines used.
7.0.3 DNA Constructs
Expression plasmids used are indicated in Table 7 and DNA constructs cloned in the
current work are prsented in Figure 7.
7.0.4 Sequencing and sequence analysis
DNA clones were sequenced using Amersham-Pharmacia’s ALF Express
(Amersham-Pharmacia Biotech, Uppsala, Sweden) and Perkin-Elmer’s ABI 373, ABI 377 and ABI
310 automatic DNA-sequencers at the Haartman Institute and at Institute of Biotechnology,
University of Helsinki. All sequence analysis was done using the GeneComposer sequence analysis
package (http://www.GeneComposer.com). Contig assembly was done using Staden sequence
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Expression plasmid Source / Reference Used in
Bmx cDNA in Bluescript SK Tamagnone et al., 1994 IV
Bmx-HA-pCIneo IV IV
c-Src Silvennoinen et al., 1993b IV
Fyn Silvennoinen et al., 1993b IV
Syk Dr. Tomas Mustelin, Couture et al., 1994 IV
Stat1α-HA Dr. Chris Schindler, Schindler et al., 1992a IV
Stat3 Dr. David Levy, Campbell et al., 1995 IV
Stat5A, MGF Dr. Berndt Groner, Wakao et al., 1994 IV
Mouse Stat5A, and its SH2 and YF
mutants
Dr. Timothy Wood I, II, III
PKC-β1 Dr. Peter Parker, Coussens et al., 1986 IV
PKC-γ Dr. Peter Parker, Coussens et al., 1986 IV
PKC-δ Dr. Peter Parker, Olivier and Parker, 1991 IV
PKC-ε Dr. Peter Parker, Schaap and Parker, 1990 IV
PKC-ζ Dr. Peter Parker, Ways et al., 1994 IV
Jak1 and its derivative Jak1-HA-pCIneo Silvennoinen et al., 1993a II, IV
Jak2 and its derivative Jak2-HA-pCIneo
Silvennoinen et al., 1993c, IV, Jak2-HA-pCIneo was used
to clone the Jak2 deletion constructs used in I, II and III
(Fig.7)
I, II, III, IV
Jak3 and its derivative Jak3-HA-pCIneo
Witthuhn et al., 1994Jak3-HA-pCIneo was used to clone
the Jak3 deletion constructs used in II (Fig.7)
II
pCI-Neo expression vector Promega, Madison, WI I, II, III, IV
GAS-Luc (WT) Dr. Richard Pine, Pine et al., 1994 I, II, II, IV
Mut-GAS-Luc Dr. Richard Pine, Pine et al., 1994 IV
Spi luciferase vector Dr. Timothy Wood, Sliva et al., 1994 IV
pEF-BOS Dr. Kalle Saksela, Mizushima and Nagata, 1990 III
PGEX-4T-1 Amersham Pharmacia Biotech III
Table 7. Expression plasmids used.
assembly package (Bonfield et al., 1995). Domain prediction was done using the Smart program
(Schultz et al., 1998; http://smart.embl-heidelberg.de/). Multiple sequence alignment was done
using Clustal W (Thompson et al., 1994).
7.0.5 Molecular modeling
The Jak2 JH2 domain was modeled based on the structure of the activated insulin receptor
kinase (Irk) at 1.9 Å resolution (Hubbard, 1997) (Protein Data Bank (PDB) (Abola et al., 1997)
entry 1ir3). The sequence alignment was performed with Clustal W and MULTICOMP (Vihinen et
al., 1992) program packages. The final alignment was obtained by manual combination of
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JH1JH2JH7 JH6 JH5 JH4
JH1
JH1JH2
JH7 JH6 JH5 JH4
JH7 JH2JH6 JH5 JH4
JH1JH2JH6
JH7 JH1JH6 JH5 JH4
JH7 JH1JH2JH6
K882E
JH1JH2JH7 JH6 JH5 JH4
JH5 JH4
E665K
JH1JH2JH7 JH6 JH5 JH4
1129
1129
1129
1129
1129
1129
1129
1129
840
808548
475251
535
808
510
173
1
1
1
1
1
1
1
1115
1129
JH1JH2JH7 JH6 JH5 JH4
11291
JH1
JH1
JH2
JH2
1129
1129
758
758
JH1JH2
1129725
JH1JH2
1129671
JH1JH2
1129619
JH1JH2
1129584
JH1JH2JH7 JH6 JH5 JH4
11291
JH1JH7 JH6 JH5 JH4
JH3
JH3
JH3
JH3
JH3
JH3
JH3
JH3
JH3
JH3
JH3
11291
744521
775761
JH2
Jh2 of Jak3
1 41 123 144 268
298
291
438 460 537 545 808 849312
808544
774516
JH1JH2
JH1JH2
1099
1099773
486
JH3
1 27 109 128 252
278
274
410 432 508 516 774 818283
JH1JH7 JH6 JH5 JH4 JH3
10991
JH2 of Jak2
775515
807545
JH7 JH1JH6 JH5 JH4
10997735151
JH3
Jak2
KN-Jak2 (K882E)
JH1-6-Jak2
Aflll-Jak2
JH2 -Jak2
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Figure 9. The Jak2 and Jak3 cDNA constructs cloned for use in I, II, III.
information from multiple sequence analysis and secondary structural information from the three
dimensional structures of tyrosine kinases. The model was built with the program InsightII
(Accelrys, San Diego, USA), as described in III.
7.0.6 Transfection of cell lines
Cells were transfected prior to confluence using the Calcium-Phosphate Transfection kit
(Invitrogen) or FugeneTM6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN) according to
manufacturer’s instructions. The cells were harvested 72 h after transfection for
immunoprecipitation and electrophoretic gel mobility shift assay and after 48 h (IV) or 24 h (I, II,
III) for luciferase assay.
7.0.7 Immunoprecipitations
The buffers used for cell lysis and following immunoprecipitation are: Triton lysis buffer
(50 mM Tris-HCl, pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM EDTA, 1% TritonX100, 50 mM
NaF, 1mM Na3VO4), kinase lysis buffer (10 mM Tris-HCl, pH 7.5, 1 % Triton X-100, 20 %
glycerol, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 1 mM Na3VO4) supplemented with protease
inhibitors PMSF, approtinin, leupeptin and pepstatin A and boiling SDS lysis buffer (0.5% SDS,
0.05 M Tris-HCl, pH 8, 1mM DTT, 50 mM NaF, 1mM Na3VO4). The SDS lysates were diluted with
1.5x RIPA buffer (1.25% NP-40, 1.25% sodium deoxycholate, 12.5 mM NaH2PO4, pH 7.2, 2 mM
EDTA, 50mM NaF, 1mM Na3VO4 with protease inhibitors) before immunoprecipitation.
For co-immunoprecipitation cells were lysed in Brij-58 buffer (10 mM Tris-HCl, pH 7.5,
0.9% Brij-58, 0.1% NP-40, 150 mM NaCl, 50 mM NaF, 1mM Na3VO4) supplemented with
protease inhibitors. Before immunoprecipitation bovine serum albumin was added to the precleared
lysates (final concentration 1%). Immunoprecipitates were washed once with Brij-58 buffer, twice
with Triton buffer, once with high salt buffer (Brij58 buffer with 350 mM NaCl) and twice with
NP-40 buffer (50 mM Tris-HCl, pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 50
mM NaF, 1mM Na3VO4). Immunoprecipitations were carried out by incubating the lysates with
specific antibodies at +4 C, following capture of the complexes using proteinA (Sigma)- or protein
G-sepharose (Amersham Pharmacia Biotech).
7.0.8 Immunoblotting
Immunoprecipitates and cell lysates were separated in SDS-PAGE (Ready Gels, Bio Rad
Laboratories) and transferred to nitrocellulose membrane. Immunodetection was performed using
specific primary antibodies, biotinylated anti-mouse or anti-rabbit secondary antibodies (Dako A/S,
Denmark) and streptavidin-biotin HRP-conjugate (Amersham Pharmacia Biotech) followed by
ECL.
7.0.9 In vitro kinase assay
For kinase assay cells were lysed in kinase lysis buffer, the lysates were
immunoprecipitated and the immunoprecipitates were washed four times with kinase lysis buffer
and twice with kinase assay buffer (10 mM HEPES, pH 7.4, 50 mM NaCl, 5 mM MgCl2, 5 mM
MnCl2, 50 mM NaF, 0.1 mM Na3VO4). The immunoprecipitates were suspended in kinase assay
buffer containing DTT (1mM). The following peptides (1 mg/ml) were used as substrates: Stat5
(AKAADGYVKPQIKQVV), Stat1 (GPKGTGYIKTELISVS), Jak1YY
(AIETDKEYYTVKDDRDS), Jak2YY (VLPQDKEYYKVKEPGES) or Jak3YY
(LLPLDKDYYVVREPGQK). 10 µCi [γ-33P] ATP or 10 µCi [γ-32P] ATP (Amersham Pharmacia
Biotech) was added to the reactions followed by 10 min incubation at room temperature and boiling
in reducing Laemmli sample buffer. The reactions were separated in 20% SDS-PAGE followed by
autoradiography or quantification of radioactivity using PhosphorImager (Fuji).
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For kinetic analysis of catalytic activity, the assay was done as described above, but 6µCi
of [γ-33P] ATP was used and the final ATP concentration was adjusted to 250 µM with unlabeled
ATP.
7.0.10 Baculovirus construction
Jak2-expressing baculovirus was constructed by cloning Jak2-HA cDNA into pVL1392
(Pharmingen) and transfecting it into Sf9 insect cells using the BaculoGoldTM Transfection Kit
(Pharmingen). Bmx-expressing baculovirus was constructed by cloning the HA-tagged Bmx cDNA
into pBluebac4 (Invitrogen, San Diego, CA) and using the Bac-N-Blue Transfection Kit
(Invitrogen) for creating the virus. The Stat1 and Stat3 baculoviruses were kind gifts from Dr. James
N. Ihle (Quelle et al., 1995b).
7.0.11 Luciferase assay
Luciferase activity was determined using Dual-Luciferase Reporter Assay System
(Promega) according to manufacturer’s instructions. The Stat-dependent luciferase activity of
GAS-Luc and Spi-Luc was normalized to the activity of the co-transfected pRLTK plasmid
constitutively expressing Renilla luciferase.
7.0.12 Purification of His-tagged proteins
Cells were lysed in kinase lysis buffer without EDTA. After clearing by centrifugation
equal amounts of protein from the lysates were diluted tenfold with Urea binding buffer (8 M urea,
50 mM NaH2PO4, 10 mM Tris, pH 8, 150 mM NaCl) and incubated with Talon metal affinity resin
(Clontech) for 30 min at room temperature. The resin was washed four times with Urea washing
buffer (8 M urea, 50 mM NaH2PO4, pH 7, 150 mM NaCl) before elution with 100 mM EDTA and
boiling in reducing Laemmli sample buffer.
7.0.13 Electrophoretic gel-mobility shift assay
For gel-mobility shift assay cells were lysed in WCE lysis buffer (50 mM Tris-HCl, pH 8,
0.5 % NP-40, 10 % glycerol, 0.1 mM EDTA, 150 mM NaCl, 50 mM NaF, 0.5 mM Na3VO4)
supplemented with protease inhibitors. Annealed GAS oligonucleotide (GAS site of murine IRF-1
gene, 5’-CTA GAG CCT GAT TTC CCC GAA ATG ATG AG-3’) or high affinity SIE
oligonucleotide (5’-GAT CAG CAT TTC CCG TAA ATC CC-3’) was end-labeled by T4
polynucleotide kinase using [γ-32P] ATP or [γ-33P] ATP (Amersham Pharmacia Biotech).
Specifically, cell lysates and 200 ng poly-dI-dC (Amersham Pharmacia Biotech) were incubated on
ice for 15’ followed by additional 15’ incubation after adding labeled GAS/SIE oligonucleotide.
Reactions were analyzed in 4.5% TBE-PAGE (2.2x TBE concentration) followed by
autoradiography. Stat5 gel-mobility shift assay was performed as described above except for that
annealed oligonucleotide corresponding to the Stat5-binding site in the β-casein gene promoter
(5’-AGATTTCTAGGAATTCAAATCC-3’) was labeled by end-filling with Klenow and [α-32P]
dCTP (Amersham Pharmacia Biotech). The reactions were analyzed in 4.5% TBE-PAGE (0.25x
TBE concentration).
Nuclear extracts were prepared as described earlier (Mui et al., 1995b). In brief, cells were
lysed in buffer A (50 mM HEPES, pH 7.5, 100 mM NaF, 10 mM sodium pyrophosphate, 2 mM
Na3VO4, 2 mM sodium molybdate, 2 mM EDTA (PSB buffer), 0.2 % NP-40, 10 mM magnesium
chloride and protease inhibitors) and centrifuged. The nuclei were washed once with buffer B (same
as A without NP-40), and finally lysed in buffer C (PSB with 0.1 % NP-40, 0.3 M NaCl, 10%
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glycerol and protease inhibitors). Nuclear extracts (6 µg), poly-dI-dC (240 ng/µl), BSA (1.5mg/ml)
and radioactively labeled GAS oligonucleotide (0.05 ng) were incubated 30’ RT, and the reactions
were resolved in 4.5% TBE (0.25X) PAGE, followed by autoradiography.
7.0.14 GST proteins
The JH1-domain and the JH1-2 domains of Jak2-HA were cloned into pGEx-4T-1, and
transformed into XL-1 Blue Escherichia coli cell line (Stratagene). Overnight cultures were diluted
1:200 in Luria media, and incubated for 3 hours following induction with 1 mM IPTG (Sigma).
Alternatively, the cells were directly lysed without induction, and used for immunoblotting.
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8 RESULTS
8.1 The JH2 domain regulates Jak2 and Jak3 kinases (I, II)
At the beginning of this thesis study, Jak tyrosine kinases had been identified as linking
cytokine receptor activation to changes in transcriptional regulation in the nucleus. Numerous
other tyrosine kinases had been cloned a couple of years ago and found to form subfamilies, and
Jak kinases were referred to as a family of “just another kinases”. However, immediately
following their cloning Jaks were found unique within other kinase subfamilies in containing
two kinase domains forming half of the entire Jak molecule, while the other half of the
molecule showed only little homology at sequence level to other kinases, or to protein domains
characterized. Therefore, it was of interest to analyze what was the function of the second
kinase domain as well as the non-homologous N-terminus in Jaks. Jak2 was first analyzed,
since it had been cloned by Dr. Silvennoinen (Silvennoinen et al., 1993c). As it became
important to find out if the results concerning Jak2 were also applicable to other Jak kinases,
Jak3 was analyzed, since it has the highest homology to Jak2 of the three other Jak kinases.
8.1.1 Deletion of JH2 increases the activity of Jak2 and Jak3 kinases (I, II)
In order to investigate the role of the JH domains in Jak2 and Jak3, a number of deletion
constructs were cloned into a mammalian expression vector, and the constructs were
transiently expressed in either 293T or COS cells. Over-expression of Jak kinases in these cell
types results in activation of the kinase without the need for stimulation with cytokines or
growth factors. The constructs used are listed in the Materials and Methods section (Figure 9).
Deletion of JH2 from Jak2 was found to result in increased tyrosine phosphorylation of
Jak2 itself as well as co-expressed Stat5, while other deletions encompassing JH domains 3-4
and 6-7, had no such effects (I: Fig. 2B and 3). A Jak2 protein containing the double kinase
domain motif (JH1-2-Jak2) was phosphorylated similarly to Jak2, and the two proteins induced
equal level of Stat5 phosphorylation, indicating that the N-terminal JH3-7 domains had no
effect on the activity of Jak2 (I: Fig. 2D and 3). However, the activity of the isolated JH1
domain was significantly increased when compared to Jak2, as detected by increased level of
autophosphorylation and activation of co-expressed Stat5 (I: Fig. 2D and 3).
A similar approach with Jak3 demonstrated an identical situation; deletion of JH2
either from full-length Jak3 or from JH1-2-Jak3, containing the JH1 and JH2 domains, resulted
in increased phosphorylation of Jak3 as well as co-expressed Stat5 (II: Fig. 3BCD). These
results indicated that the JH2 domain negatively regulated the activity of Jak2 and Jak3 in
mammalian cells. Furthermore, the isolated JH1 domains of Jak2 and Jak3 were functional
kinases, when expressed alone, and the presence of JH2 reduced the activity of JH1 in
mammalian cells.
8.1.2 The effect of JH2 on in vitro kinase activity of Jak2 and Jak3 (I, II, III)
The effect of JH2 on the activity of Jak2 and Jak3 was also studied using in vitro kinase
assay. Upon deletion of JH2 the activity of Jak2 was increased 5-10 fold, while deletion of JH
domains 3-4, 6-7 or 3-7 had no such effects (I: Fig. 2AB). Also, the isolated JH1 domain had
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over 50-fold higher activity when compared to Jak2 (I: Fig. 2B). Thus, the results from
mammalian cells correlated well with the in vitro kinase data indicating negative regulation of
Jak2 by the JH2 domain.
The deletion of JH2 in Jak3 only slightly increased the kinase activity of Jak3, and the
isolated JH1 domain had twofold activity when compared to Jak3 (II: Fig. 3E). Interestingly,
JH1-2-Jak3, containing the double kinase domain motif, showed reduced activity when
compared to JH1, indicating downregulation of JH1 activity by JH2 (II: Fig. 3E). Of note is that
the activity of JH1-2-Jak3 was reduced by 30% when compared to Jak3. Thus, the results from
in vitro kinase assay showed negative regulation of Jak3 JH1 by the JH2 domain. However, the
effect of JH2 on Jak3 kinase activity was not as pronounced as in Jak2.
To gain insight into the mechanism by which JH2 negatively regulated the in vitro
kinase activity of Jak2, a kinetic analysis of kinase activity was performed. The Jak2 JH1
domain or the double kinase domain of Jak2, JH1-2-Jak2, was expressed in 293T cells, and the
activity of the immunoprecipitated proteins was analyzed in regard to time and varying
substrate peptide concentration (III: Fig. 2). Both JH1-Jak2 and JH1-2-Jak2 showed a typical
linear relationship between time and phosphorylation of the substrate. The activity of the
kinases increased similarly with increasing substrate concentrations, and JH1-Jak2 and
JH1-2-Jak2 reached their half-maximal activities in similar peptide concentrations. However,
the highest activity of JH1 was approximately 5-10 times higher than that of JH1-2. Thus, the
JH2 domain decreases the maximal velocity (Vmax) of Jak2, but does not significantly affect
the Km for a peptide substrate.
8.1.3 The Stat5 SH2 domain is required for activation by Jak2, but not by
JH2∆-Jak2 (I)
The SH2 domains of Stats are critical for their activation by Jak kinases (Gupta et al.,
1996). In accordance with this, Jak2 was found to phosphorylate Stat5, but not its SH2 mutant
carrying a R618L substitution (I: Fig. 4). However, the Jak2 deletion mutants lacking JH2
activated both Stat5 and its SH2 mutant (I: Fig. 4). Deletion of JH domains 3-7 in Jak2 did not
change the requirement for the SH2 domain in activation of Stat5, although increasing amounts
of JH1-2-Jak2 were used resulting in higher tyrosine phosphorylation of JH1-2-Jak2 than
JH2∆-Jak2 (I). Thus, the high catalytic activity of the JH2 deletion mutants was not the
explanation for phosphorylation of the SH2 mutant Stat5.
Phosphorylation of tyrosine 694 in Stat5 is required for dimerization and activation of
Stat5. To test if JH2∆-Jak2 phosphorylated specifically this residue in Stat5, JH2∆-Jak2 was
co-expressed with Y694F-Stat5 in 293T cells. JH2∆-Jak2, as well as Jak2, was unable to
phosphorylate the Y694F mutant of Stat5 (I). This indicated that despite of its high activity,
JH2∆-Jak2 retains its specificity by phosphorylating only the critical tyrosine 694 in Stat5.
Taken together, these results indicate interdependence between the Jak2 JH2 domain and the
Stat5 SH2 domain in Jak2-mediated activation of Stat5, suggesting that the JH2 domain affects
interactions of Jak2 with its target proteins.
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8.2 JH2 is required for cytokine receptor signaling (I, II)
8.2.1 The JH2 domain inhibits of basal activity of Jak2 and Jak3 (I, II)
To analyze the effect of JH2 in cytokine receptor signal transduction, Jak2 and Jak3
kinases lacking JH2 domains were expressed in cells, where activation of Jaks is dependent on
stimulation with IFN-γ or IL-2, respectively (I: Fig. 7, II: Fig. 6). Activation of Jaks was
monitored using a Stat-dependent luciferase construct. Wild-type Jak kinases showed very
little, if at all, Stat activation in the absence of stimulation, but responded with increased
activity to cytokine treatment. However, both JH2 deletion mutants showed unregulated
activity by inducing constitutively elevated Stat activity in the absence of cytokine stimulation.
This indicated that the function of JH2 was to negatively regulate basal Jak activity in the
absence of cytokine stimulation, where Jaks are supposed to be inactive. It is of note, however,
that upon deletion of JH2 from Jak2, Stat1 activation was much more prominent than Stat5
activation resulting from deletion of JH2 in Jak3. Thus, it was concluded, together with the in
vitro kinase assay data, that the negative regulatory role of JH2 might not be as important in
Jak3 as it is in Jak2.
8.2.2 The JH2 domain is required for cytokine-inducible activation of
signal transduction (II)
A second result from the analysis of the function of JH2 in cytokine receptor signaling
was that Jak2 and Jak3 kinases lacking JH2 were unresponsive to cytokine stimulation (II: Fig.
6). Wild-type Jak2 and Jak3 showed low basal activity, and upon stimulation, a clear induction
in Stat activation. However, the elevated level of basal signaling mediated by JH2∆-Jak2 and
JH2∆-Jak3 was not further increased when the cells were stimulated with IFN-γ or IL-2,
respectively. This indicated that the JH2 domains of Jak2 and Jak3 were required for
cytokine-inducible activation of signal transduction.
8.2.3 The effect of JH2 in Jak activation in cytokine receptors (II)
To find out, if JH2 was required for cytokine-inducible activation of the Jak kinases
themselves, in addition to being required for inducible Stat activation, activation of JH2∆-Jak2
was analyzed in IFN-γ receptor signaling. In Jak2-negative cells transfected with JH2∆-Jak2,
IFN-γ had no effect on tyrosine phosphorylation of JH2∆-Jak2, while in Jak2-transfected cells
IFN-γ-induced increased tyrosine phosphorylation of wild-type Jak2 (II: Fig. 7A).
Furthermore, JH2∆-Jak2 showed significantly increased tyrosine phosphorylation when
compared to that of Jak2. Thus, JH2 was found to be required for inhibition of basal Jak2
activity. In addition, JH2 was required for rendering Jak2 competent to respond to cytokine
stimulation with increased activity.
Jak kinase activation in response to IFN-γ most likely requires the reciprocal
interaction of Jak1 and Jak2. Thus, it was possible that in the absence of JH2, the Jak1 and Jak2
kinases were unable to interact, resulting in the lack of IFN-γ-inducible activation of
JH2∆-Jak2. Therefore, kinase-inactive forms of Jak2 and JH2∆-Jak2 were co-expressed with
Jak1 (II: Fig. 7B). The analysis of the tyrosine phosphorylation levels of Jak2 and JH2∆-Jak2
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indicated that Jak1 phosphorylated both Jak2 proteins equally well. Thus, JH2 was not required
for interaction of Jak1 and Jak2 as such, suggesting that inducible activation of JH2∆-Jak2 was
specifically disturbed in the context of the IFN-γ receptor.
8.3 Comparison of JH2 and JH1 domains of Jak2 and Jak3 (II)
8.3.1 The JH2 domains of Jak2 and Jak3 are functionally similar, but not
identical (II)
The results from the analysis of Jak2 and Jak3 indicated that JH2 negatively regulated
both kinases, but the results also suggested that negative regulation of Jak3 was not as
significant as that of Jak2. To directly compare the function of the JH2 domains in Jak2 and
Jak3, chimeric constructs were cloned, in which the JH2 domain of Jak2 was transferred to Jak3
and vice versa. These chimeric constructs were analyzed in 293T or COS cells. Tyrosine
phosphorylation of the chimeric proteins was comparable to that of wild-type Jak2 and Jak3,
and similarly, the co-expressed Stat5 was equally phosphorylated by the chimeric and
wild-type Jak kinases (II: Fig. 4 and 5). Thus, the JH2 domains were found to be
interchangeable between Jak2 and Jak3.
The chimeric constructs were also analyzed in cytokine receptor signaling. Jak232,
containing the JH2 domain of Jak3, behaved as wild-type Jak2 in IFN-γ signaling by having
low basal activity and inducing significant increase in Stat activation following IFN-γ
stimulation (II: Fig. 6B). Thus, the JH2 domain of Jak3 was able to restore the wild-type
phenotype of Jak2.
Jak323, containing the JH2 domain of Jak2, had reduced basal activity when compared
to JH2∆-Jak3 and showed induction in Stat5 activity following IL-2 treatment, although the
induction was significantly lower than that induced by wild-type Jak3 (II: Fig. 6A). This
suggested that JH2 of Jak2 could not fully complement the Jak3 JH2 domain in IL-2 receptor
signaling.
8.3.2 Comparison of kinase activity of Jak1, Jak2, and Jak3 kinases (II)
Having analyzed the effect of various JH deletions on the activity of Jak2 and Jak3, the
activity of full-length Jak kinases was compared. Jak1, Jak2 and Jak3 were expressed in 293T
cells, and the kinase activity as well as tyrosine phosphorylation of the expressed proteins were
analyzed (II: Fig. 1). Jak2 had very low kinase activity and tyrosine phosphorylation when
compared to those of either Jak1 or Jak3. Interestingly, Jak1 and Jak3 showed different
substrate peptide preference. Jak1 was most efficient in phosphorylating a peptide containing
the phosphorylation site of Stat5, while Jak3 preferred peptides containing the
autophosphorylation site sequences of Jak1, Jak2 and Jak3.
The activity of the isolated tyrosine kinase domains of Jak2 and Jak3 was also
compared, and this analysis showed that the JH1 domain of Jak2 had significantly lower
activity than that of Jak3 (II: Fig. 2).
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8.4 The mechanism of JH2-mediated inhibition of Jak2 (I, III)
8.4.1 PTPase inhibitors activate Jak2 independently of JH2 (I)
To elucidate the mechanism of JH2-mediated inhibition of Jak2 activity, several
possibilities were considered. First, Jak2 might be a target for a protein tyrosine phosphatase,
whose activity would be dependent on the presence of JH2. Therefore, the effect of PTPases
was analyzed by treating cells expressing different Jak2 deletion mutants with phosphatase
inhibitors (I: Fig. 5). In cells treated with pervanadate, tyrosine phosphorylation of Jak2 was
increased. Similarly, pervanadate increased phosphorylation of JH1 and JH2∆-Jak2, indicating
that in the absence of JH2, Jak2 was regulated by PTPases. Thus, it was concluded, that
PTPase-mediated regulation of Jak2 might not be abrogated by deletion of JH2, and that JH2
might regulate Jak2 in other ways than through the recruitment of a PTPase.
8.4.2 The JH2 domain inhibits the activity of co-expressed JH1 (I)
Another possible mechanism for JH2-mediated inhibition was that JH2 interacted with
JH1, and thereby inhibited its kinase activity. To test this, co-immunoprecipitation studies were
undertaken using 293T cells expressing JH1 and JH2. However, the expression of JH2
remained extremely low, and co-immunoprecipitation could not be analyzed, although
numerous different JH2 expression plasmids were cloned for this purpose. Therefore, it was
questioned, if JH1 was able to interact with Jak2, and if so, what JH regions affect this
interaction. JH1 was expressed together with Jak2 or Jak2 lacking JH1 (JH1∆-Jak2), and found
to co-immunoprecipitate with both Jak2 and JH1∆-Jak2 (I: Fig. 6A). However,
co-immunoprecipitation of JH1 with JH1∆-Jak2 was much weaker than with Jak2. This
indicated that JH1 could interact with Jak2 in two different ways. First, JH1 interacted with
another JH1, since deletion of JH1 reduced the association of JH1 with Jak2. This type of
interaction is supposed to be important during activation of Jak2. Second, JH1 could associate
with JH regions 2-7 in Jak2, but this association was weaker than the JH1-JH1 interaction.
Deletion of JH domains 3-7 did not affect interaction of JH1 with Jak2 suggesting that JH1 did
not interact with domains 3-7 in Jak2 (I).
To analyze the effect of the interaction of JH1∆-Jak2 with JH1, JH1 was co-expressed
with JH1∆-Jak2, or with a kinase-inactive Jak2. The kinase inactive form of Jak2 is able to
inhibit activation of Jak2 when co-expressed, most probably by competing in dimerization with
wild-type Jak2, which is required for autophosphorylation and subsequent activation (Zhuang
et al., 1994). Co-expression of either JH1∆-Jak2 or kinase-inactive Jak2 reduced the activity of
JH1 as detected by lower level of autophosphorylation of JH1 as well as by reduced level of
substrate peptide phosphorylation (I: Fig. 6BC). On the contrary, co-expression of JH3-7
domains with JH1 had no effect on autophosphorylation of JH1 (I: Fig. 6D). In conclusion, the
results demonstrated that interaction of JH1∆-Jak2 with JH1 was associated with inhibition of
JH1 activity, while no inhibition was obtained if JH2 was further deleted. Thus, the results
suggested that JH1 was inhibited by interaction with JH2.
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8.4.3 Autoinhibition of Jak2 by the JH2 domain in E. coli (III)
The results from mammalian cells suggested that JH2 regulated JH1 by interacting with
it. Again, several possibilities existed; JH2 might keep JH1 in a conformation where catalytic
activity was autoinhibited or directly prevent the access of ATP or substrates to the catalytic
cleft, or alternatively, recruit a regulatory protein to the vicinity of JH1, which might be
responsible for inhibition of JH1 activity.
To distinguish between these possibilities, JH1-Jak2 and JH1-2-Jak2 were expressed as
GST-fusion proteins in bacterial cells (III: Fig. 1). Prokaryotes do not have tyrosine kinases,
and thus are not expected to have proteins regulating these kinases. JH1-2-GST and JH1-GST
were both tyrosine phosphorylated, indicating that the expressed proteins were active in
bacterial cells. However, phosphorylation of JH1-GST was much higher than that of
JH1-2-GST, indicating that JH1-GST was more active than JH1-2-GST. Moreover, a number
of bacterial proteins were tyrosine phosphorylated in JH1-GST expressing cells, but not in
JH1-2-GST cells. Thus, JH2 regulated the activity of JH1 also in bacterial cells, indicating that
JH2-mediated regulation of Jak2 was an intrinsic property of the Jak2 molecule and not
dependent on additional regulatory proteins, strongly suggesting for JH2-mediated
autoinhibition of Jak2.
8.5 Autoinhibitory regions in the JH2 domain (III)
To investigate the possible mechanism for JH2-mediated autoinhibition of Jak2, an
attempt was started to identify possible regions in JH2 required for Jak2 regulation. The
backbone construct JH1-2-Jak2 was sequentially deleted, starting from the N-terminus of JH2,
to create five deletion constructs. The deletion constructs were co-expressed with Stat5 in 293T
cells (III: Fig. 5BC). This analysis revealed three inhibitory regions (IR1, IR2 and IR3) that
when deleted from the JH1-2-construct, resulted in increased phosphorylation of co-expressed
Stat5. IR1 contained amino acids 618-670 located at the border of the N-terminal and
C-terminal lobes of the JH2 domain. IR2 and IR3 were located in the C lobe and encompassed
amino acids 725-757 and 758-807, respectively. Localization of the inhibitory regions was
based on molecular modeling of the 3-dimensional structure of the JH2 domain of Jak2 (III:
Fig. 3).
IR3 is a 50-amino acid region at the C-terminus of JH2 directly preceding the linker
domain and JH1, and it was found to significantly inhibit JH1, suggesting direct interaction
between IR3 and JH1 (III: Fig. 5C). The model structure of JH2 suggested that IR3 might fold
properly as an independent unit, thereby supporting the finding that IR3 alone was able to
inhibit JH1. The addition of IR2 and IR1 enhanced IR3-mediated inhibition of JH1 (III: Fig.
3B).
The presence of an inhibitory region in the C-terminus of Jak2 JH2 was further
strengthened by the finding that two JH2 deletions differing by a 60-amino acid C-terminal JH2
region had different activities (III: Fig. 4BCD). Specifically, the entire JH2 domain was deleted
in JH2∆-Jak2, but the 60 residues from the C-terminus of JH2 were present in BglII∆-Jak2.
BglII∆-Jak2 showed increased activity when compared to Jak2, indicating that the inhibitory
regions present in JH2 were missing in BglII∆-Jak2. These included the previously identified
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IR1 and IR2. However, the activity of BglII∆-Jak2 was lower than that of JH2∆-Jak2,
indicating that the C-terminal 60 amino acids in JH2, including IR3, contained an inhibitory
region.
To further analyze the role of IR3 in JH2-mediated regulation of Jak2, alanine
mutations were created in the 758-Jak2 construct. The activity of 758-Jak2 was increased when
amino acids 763-765 (LQF), 765-767 (FYE) or 771-773 (QLP) were substituted with alanines
(III: Fig. 6B). Molecular modeling suggested that residues 763L, 764Q, 765F, E767, 771Q and
773P in IR3 might be exposed on the surface of the JH2 domain, thus being able to interact with
JH1. Y766, on the other hand, projects inward in the model and is not likely to interact with
JH1, and consequently, may not be phosphorylated. The molecular model also showed that
residues 763-767 are located in αG helix, and the helical structure might be an important
structural feature and locally distorted by alanine mutations, thus causing deregulation of
inhibition.
The sequence, where the alanine mutations were introduced was also deleted from
full-length Jak2 (761∆-Jak2), and this resulted in increased phosphorylation of Jak2 and
elevated level of basal IFN-γ signaling (III: Fig. 7BC). However, 761∆-Jak2 had lower activity
than JH2∆-Jak2, where the entire JH2 domain was deleted, in accordance with the finding that
IR1 and IR2 also inhibited Jak2 activity. These results indicated that IR3 is involved in
inhibition of basal Jak2 activity, but it is not solely responsible for inhibition. Rather, inhibition
of Jak2 is dependent on multiple sites in JH2.
8.6 The Bmx kinase induces activation of the Stat signaling
pathway (IV)
The Bmx tyrosine kinase had been cloned at the Haartman Institute in 1994
(Tamagnone et al., 1994) based on screening of a bone marrow derived cDNA library. In 1995,
when the current work was started, not much was known about the Bmx kinase. For instance, it
was not known, what cytokines or growth factors might activate Bmx or what substrate proteins
were activated by the Bmx kinase. To study the signaling mechanisms of the Bmx kinase, a
collaborative study was started with the laboratory of Prof. Kari Alitalo.
The possibility that Bmx might function in the newly identified Stat pathway was
studied. Bmx was expressed in COS cells, and the activity of endogenous Stat proteins was
analyzed. COS cells express significant amounts of Stat1, but not other Stats. Stat1 was found
activated in Bmx-expressing cells as detected by the ability of Stat1 to bind DNA, and the level
of Stat1 activation was comparable to that induced by Jak2, which was used as a control (IV:
Fig. 5).
To analyze the ability of Bmx to activate also other Stat proteins, Bmx was
co-expressed with Stat3 and Stat5, and also, as a control, Stat1 in COS cells. Bmx induced
activation of all the Stat proteins analyzed at a similar level, as did Jak2 (IV: Fig. 1, 2, 3 and 4).
In contrast, other cytoplasmic tyrosine kinases tested, namely c-Src, Syk and Fyn, showed only
very little Stat activation (IV: Fig. 1 and 2). To rule out Jak kinase-mediated activation
mechanism for Bmx-induced Stat activation, Bmx- and Jak2-expressing baculoviruses were
created. In insect cells, Jak2 and Bmx induced activation of Stat1 and Stat3, but
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phosphorylation of Stat3 by Bmx was much higher than that induced by Jak2 (IV: Fig. 7 and 8).
Furthermore, endogenous Jak activation could not be detected in Bmx-expressing cells (IV:
Fig. 6). Altogether, these results indicated that Bmx was able to induce activation of multiple
Stat proteins, and thereby suggested that Bmx might function in signaling pathways leading to
Stat activation.
Other Btk/Tec family kinases, such as Btk and Itk, had been found to be regulated by
members of the PKC family of serine/threonine kinases. In the case of Btk, the PKC isoforms
α, β1, β2, ε and ζ had been found to inhibit Btk activity, whereas the activity of Itk was
enhanced by PKCα, PKCβ1 and PKCβ2 (Yao et al., 1994; Kawakami et al., 1995; Yao et al.,
1997).
Therefore, it was analyzed, if Bmx was also a target for regulation by PKC. Bmx was
co-expressed with different PKC isoforms and Stat1, and the effect of PKC on Stat1 activation
was analyzed (IV: Fig. 9 and 10). PKC-δ, but not other PKC isoforms, PKC-β1, PKC-ε or
PKC-ζ, significantly inhibited activation of Stat1 by Bmx, suggesting that PKC-δ negatively
regulated signaling by Bmx.
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9 DISCUSSION
Protein tyrosine kinases are essential mediators of cellular signaling pathways.
Reversible protein phosphorylation plays a key role in diverse cellular processes such as
proliferation, differentiation and apoptosis. The activity of PTKs is normally tightly regulated.
Abrogation of kinase regulation, for example due to mutations in PTKs themselves, has been
found to result in hyperactivated kinases, and even cancer (reviewed in Blume-Jensen and
Hunter, 2001). Many of the known oncogenes code for malfunctioning PTKs. Therefore,
understanding the normal function and regulation of tyrosine kinases is of critical importance.
The current work has focused on kinases from the Jak and Btk/Tec non-receptor PTK families,
their regulation and functions in the Stat signaling pathway.
9.1 Bmx-induced Stat activation
In this work, activation of Stat transcription factors was identified as a potential
downstream signaling event for the Bmx tyrosine kinase (IV). Expressed Bmx induced
activation of endogenous Stat1, as well as co-expressed Stat1, Stat3 and Stat5 (IV). While these
studies did not show in vivo activation of Stats by Bmx, subsequently Bmx has been shown to
activate Stats in similar as well as in more physiological systems (Wen et al., 1999; Jui et al.,
2000; Tsai et al., 2000), supporting the results from the current work (IV). One possible
explanation for Bmx-induced Stat activation is that Bmx activates endogenous Jak kinases.
However, endogenous Jak activation in Bmx-transfected cells was not detected (IV).
Furthermore, the transfected Bmx and Jak kinases were equally effective in induction of Stat
activation (IV). This would be unlikely if Bmx works through activation of endogenous Jak
kinases. In addition to Bmx, another family member, Btk, directly interacts and phosphorylates
Stat5 in vitro (Mahajan et al., 2001), but the prototype member of the Btk/Tec family, Tec, is
unable to induce Stat activation (Quelle et al., 1995b). Btk is crucial in activating Stat5 through
BCR (Mahajan et al., 2001), where Stat activation has been found to occur within minutes after
activation of BCR, although Jaks are not activated (Karras et al., 1996).
A number of receptor tyrosine kinases, such as EGFR and PDGFR have been found to
directly phosphorylate Stat proteins (Quelle et al., 1995b; David et al., 1996; Leaman et al.,
1996; Park et al., 1996b; Vignais et al., 1996; Vignais and Gilman, 1999; Paukku et al., 2000).
In cancer cells, constitutive Stat activation is dependent on upstream tyrosine kinases, often
other than Jaks. For example, NPM/ALK induces activation of Stat3 and Stat5, and BCR/ABL
directly activates Stat5, although Stat5 may not be required for transformation by BCR/ABL
(de Groot et al., 1999; Nieborowska-Skorska et al., 1999; Sexl et al.,
2000Nieborowska-Skorska et al., 2001; Sonoyama et al., 2002; Zhang et al., 2002a).
Activation of Stat3 is required for tumorigenesis induced by the Met receptor tyrosine kinase
(Zhang et al., 2002b). Overexpressed Syk, c-Src or Fyn showed much weaker ability to activate
Stats as compared to Bmx or Jak2, illustrating clear differences in their substrate specificity
(IV). c-Src has been found to activate Stat3 in NIH3T3 cells, but v-Src was able to induce much
higher level of Stat3 activation (Yu et al., 1995). Although v-Src has been found to directly
activate Stats (Cao et al., 1996; Chaturvedi et al., 1998), it is not entirely clear if
v-Src-mediated Stat activation is always direct. Overexpression of v-Src in a myeloid cell line
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induces constitutive activation of Stat1, Stat3 and Stat5, but only Stat3 is activated directly by
v-Src (Chaturvedi et al., 1998). Thus, Src-induced Stat activation may depend on other kinases,
such as Jaks, which show increased activation in v-Src transformed cells (Campbell et al.,
1997; Murakami et al., 1998). In some cases Src and Jak are suggested to co-operate in Stat
activation (Zhang et al., 2000b). On the contrary, Bmx enhances v-Src-mediated Stat activation
in fibroblast cells, which can be explained by a sequential activation pathway: v-Src positively
regulates the activity of Bmx, which activates Stat3 more efficiently than v-Src, in agreement
with the results in the current work (IV; Tsai et al., 2000). Dominant negative Bmx also reduces
v-Src -mediated transformation and, although Bmx itself does not induce transformation of
NIH3T3 cells, the results indicate that the Src-Bmx-Stat3 pathway is important in cellular
transformation (Tsai et al., 2000). Thus, depending on the particular receptor and on the
cellular contex other tyrosine kinases, in addition to Jaks, regulate the Stat pathway, and
Tec/Btk kinases have been found to be among those (IV; Wen et al., 1999; Tsai et al., 2000;
Mahajan et al., 2001). Based on these and similar data, the Stat signaling pathway is sometimes
suggested to be more appropriately called the “PTK-Stat” pathway (reviewed in Rane and
Reddy, 2000; Reddy et al., 2000; Rane and Reddy, 2002).
Bmx has been implicated in malignant processes of various cell types. In contrast to
other Tec kinases, Bmx is expressed also outside the hematopoietic system in a variety of cells
and tissues, including breast, lung and prostate tissues as well as epithelial and endothelial cells
(Tamagnone et al., 1994; Ekman et al., 1997; Qiu et al., 1998; Rajantie et al., 2001). The
expression of Bmx in mammary epithelial cells is regulated during mammary gland
development (Bagheri-Yarmand et al., 2001). Bmx is also highly expressed in human breast
cancer cell lines, where expression of a dominant negative Bmx inhibits the tumorigenic
phenotype of these cells (Bagheri-Yarmand et al., 2001). Bmx can also enhance
anchorage-independent growth of a non-invasive breast cancer cell line (Bagheri-Yarmand et
al., 2001). In this context, it is interesting to note that Stat5A is essential for mammary gland
development, and that constitutive activation of Stat3 frequently occurs in breast cancers
(Garcia et al., 1997; Sartor et al., 1997; Teglund et al., 1998). Furthermore, constitutive Stat
activation is detected in tumor-infiltrated lymph nodes, suggesting it may be a property of more
invasive tumors (Bowman et al., 2000). A role for Bmx in metastasis has been suggested by
studies showing that a dominant negative Bmx inhibits the motility of metastatic mammary and
prostate carcinoma cells, where Bmx is highly expressed (Chen et al., 2001).
Bmx has been linked to Stat activation in malignant processes, but as to yet, evidence is
missing for participation of Bmx in Stat activation in its normal cellular pathways (Tsai et al.,
2000). By the time the work (IV) was started, no upstream activator for Bmx was known, and
the identification of Stat transcription factors as substrates for Bmx was the first downstream
signaling event reported for Bmx, and among the first substrates identified for any of the
Btk/Tec kinases. Currently, Bmx is known to be activated by IL-3, IL-6 and GM-CSF, through
endothelium-specific receptors Tie-2/Tek and vascular endothelial growth factor receptor 1
(VEGFR-1) as well as heterotrimeric G proteins (Mao et al., 1998; Qiu et al., 1998; Ekman et
al., 2000; Rajantie et al., 2001). All these upstream activators also activate Stats (Marrero et al.,
Signaling through the Jak/Stat pathway: Regulation of tyrosine kinase activity 57
1995; Mui et al., 1995b; Korpelainen et al., 1999; Bartoli et al., 2000). The phenotype of Bmx
knockout mice is normal, however, and does not reveal any nonredundant functions for Bmx
(Rajantie et al., 2001).
Recently, Bmx was found to mediate integrin signaling and cell migration through
FAK (Chen et al., 2001). FAK binds, through its FERM domain, to the PH domain of Bmx,
which results in activation of Bmx. Activation of Bmx has been found to result in
reorganization of actin filaments (Hamm-Alvarez et al., 2001). Disruption of the FAK-Bmx
interaction inhibits migration of normal as well as metastatic prostate and mammary cancer
cells (Chen et al., 2001). Bmx has been found to activate RhoA, a small GTPase, involved in
cytoskeletal reorganization, suggesting that Bmx enhances cell migration through activation of
RhoA (Mao et al., 1998Kim et al., 2002). Interestingly, a role for Stat3 has been implicated in
the motility of epidermal cells (Sano et al., 1999).
FAK-mediated activation of Bmx does not require PI3K, which is now known to
activate Bmx (Qiu et al., 1998; Ekman et al., 2000), nor lipid binding by the PH domain. This
suggests that FAK activates Bmx by inducing a conformational change in Bmx, which disrupts
inhibition mediated by the Bmx PH domain (Chen et al., 2001). Similarly, a protein tyrosine
phosphatase D1 (PTPD1) induces Bmx activation through binding to the PH domain, which
results in increased activation of Stat3 in salivary Pa-4 cells (Jui et al., 2000).
All in all, Bmx has been found to be involved in several different, and even opposing
cellular processes, such as apoptosis (Ekman et al., 2000; Wu et al., 2001) and anti-apoptosis
(Xue et al., 1999), differentiation (Qiu et al., 1998), cell migration (Chen et al., 2001; Pan et al.,
2002) and cell transformation (Tsai et al., 2000). Thus, the function of Bmx appears to be
complex, and most likely is dependent on a particular cellular context, where Bmx is expressed.
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Figure 10. Schematic presentation of signaling by Btk/Tec kinases, modified from Qiu and Kung, 2000.
9.2 Bmx signaling is regulated by PKCδ
PKCδ, but not β1, ε or ζ isoforms, was found to regulate Bmx signaling by inhibiting
Bmx-mediated tyrosine phosphorylation of Stat1 (IV). PKCδ belongs to the group of novel
PKCs (PKCδ,, ε, η, θ), which are regulated by diacylglycerol, but not calsium, distinguishing
them from classical (PKCα, β, γ) and atypical (ζ, λ) PKCs. Hematopoietic transmembrane
receptors, such as cytokine, antigen and Fc receptors, commonly activate PKC. In PKCδ
signaling, PKCδ often becomes tyrosine phosphorylated, which modulates its kinase activity.
For example, substance P, carbacol, EGF-, IL-6- and IgE-induced signaling pathways have
been found to induce tyrosine phosphorylation of PKCδ (Haleem-Smith et al., 1995; Soltoff
and Toker, 1995; Denning et al., 1996; Jain et al., 1999). Co-expression of Bmx with PKCδ
also induced tyrosine phosphorylation of PKCδ indicating possible regulation of PKCδ by
Bmx (IV).
The mechanism by which PKCδ inhibits Bmx-induced Stat activation is currently
unknown. Recently, PKCδ has been found to participate in IL-6- and type I IFN-induced Stat
pathways (Jain et al., 1999; Schuringa et al., 2001; Uddin et al., 2002). IL-6 stimulation
induced tyrosine phosphorylation and activation of PKCδ, and its concomitant association with
Stat3 leading to serine phosphorylation of Stat3. This resulted in decreased tyrosine
phosphorylation, DNA binding and transcriptional activation by Stat3 (Jain et al., 1999), in
agreement with the results found in the current work (IV). However, serine phosphorylation by
PKC-δ has also been reported to increase transcriptional activation by Stat3 (Schuringa et al.,
2001). PKCδ also enhances transcriptional activity of Stat1 by α/β IFNs (Uddin et al., 2002).
Thus, PKCδ has been found to both inhibit and enhance Stat signaling. A similar phenomenon
has been described for ERK-mediated regulation of Stat3. Stat3 tyrosine phosphorylation was
found to be negatively regulated through the ERK pathway (Chung et al., 1997b; Jain et al.,
1998), while ERK was also found to phosphorylate Stat3, resulting in increased transcriptional
activity of Stat3 (Turkson et al., 1999). The different results concerning the role of ERK in
Stat3 signaling have been suggested to depend on the expression level of ERK, low amounts
being inducing and high levels inhibiting to Stat3 (Turkson et al., 1999). Whether this explains
the different effects of PKCδ on Stat activation is not known.
Bmx itself might also be the target for negative regulation by PKCδ. Several PKC
isoforms have been implicated in signaling by Btk/Tec kinases (Yao et al., 1994; Kawakami et
al., 1995; Yao et al., 1997Johannes et al., 1999; Kawakami et al., 2000; Kang et al., 2001;
Crosby and Poole, 2002). PKCβ negatively regulates Btk activity by directly phosphorylating a
serine residue in the TH domain of Btk (Yao et al., 1994; Kang et al., 2001). Mutation of the
serine residue results in enhanced tyrosine phosphorylation and membrane localization of Btk
as well as increased signaling through BCR and FcεRI (Kang et al., 2001). The PKCβ
phosphorylation site is conserved in other Btk family members, except for Bmx, suggesting
that the activity of Bmx is regulated differentially from other family members. Interestingly,
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PKCδ and PKCα were found to inhibit Stat activation through the IL-3R, and this was found to
result from direct inhibition of Jak2 activity by PKC (Kovanen et al., 2000). However,
regulation of Bmx by PKCδ could not be detected (IV).
PKCδ might also activate a phosphatase capable of dephosphorylating Stats or Bmx. In
primary monocytes, IFN-α signaling has been found to be inhibited by phorbol esters through
an as yet uncharacterized protein tyrosine phosphatase (Petricoin et al., 1996). Phorbol esters
have also been found to increase the catalytic activity and expression of the SH2-containing
phosphatase, SHP-1, which is implicated in the downregulation of cytokine receptor signaling
by dephosphorylating the Jak kinases (Uchida et al., 1993). Yet, it is possible that PKCδ
induces expression of proteins negatively regulating Stat activity, such as SOCS or PIAS
proteins.
9.3 The JH2 domain regulates the basal activity of Jak2 and
Jak3
The central finding in this thesis work is the identification of the pseudokinase domain,
JH2, as a regulatory domain in Jak2 (I) and Jak3 (II) kinases. Deletion of JH2 from Jak2 and
Jak3 resulted in increased Jak activity and constitutive Stat activation, indicating a negative
regulatory role for the JH2 domain (I, II). Although negative regulation by JH2 was more
evident in Jak2 than in Jak3, the chimeric constructs demonstrated that the Jak3 JH2 domain
was also an inhibitory domain (II).
At the beginning of the current work, not much was known about the function of the
JH2 domain in Jaks, but in the course of these studies a number of reports were published,
stating that JH2 regulated Jak kinases (I, II, III, Duhe and Farrar, 1995; Frank et al., 1995;
Velazquez et al., 1995; Luo et al., 1997; Sakai and Kraft, 1997; Barahmand-Pour et al., 1998;
Chen et al., 2000; Yeh et al., 2000). Consistent with the results from this study, a negative
regulatory role has been assigned to Jak2 and Drosophila Jak, Hop, in studies by others (Luo et
al., 1997; Barahmand-Pour et al., 1998). In yeast, deletion of JH2 increased Jak2-mediated
activation of Stat5, but the isolated JH1 domain was less active than Jak2 (Barahmand-Pour et
al., 1998). A mutation in the Drosophila Hop JH2 domain produced a hyperactive kinase and
induced hematopoietic neoplasia in the fly (Luo et al., 1997). The corresponding mutation in
Jak2 resulted also in increased Jak2 activity (Luo et al., 1997; I), although deletion of the entire
JH2 domain resulted in much higher activity (I). In Hop, however, deletion of JH2 resulted in
inactivation of the kinase (Luo et al., 1997). Similarly, in both Tyk2 and Jak3, deletion of JH2
resulted in loss of kinase activity, which suggested an essential role for JH2 in maintaining
overall activity of these kinases (Velazquez et al., 1995; Chen et al., 2000).
The analysis of SCID patients revealed mutations in various Jak3 JH domains, and
interestingly, also in the Jak3 JH2 domain (Candotti et al., 1997). The SCID phenotype
suggested that the JH2 mutations impaired Jak3 activity. Indeed, when the Jak3 mutants were
analyzed, they did not mediate IL-2 signaling in cells, and were inactive in an in vitro kinase
assay (Chen et al., 2000). However, the Jak3 mutants were hyperphosphorylated in cells
compared to wild-type Jak3. The increased tyrosine phosphorylation of Jak3 mutants was most
likely dependent on their own catalytic activity, since mutation of K930 in the JH1 domain of
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Jak3 abolished their in vivo phosphorylation (Chen et al., 2000). Very similar results were also
obtained with Tyk2. Artificially made mutations in the Tyk2 JH2 domain abolished the in vitro
kinase activity of the Tyk2 mutants, with a concomitant loss of IFN-α signaling (Yeh et al.,
2000). However, tyrosine phosphorylation of the Tyk2 mutants was increased in cells
compared to wild-type Tyk2, and again, mutation of the conserved lysine K855 in JH1
abolished in vivo tyrosine phosphorylation (Yeh et al., 2000). Currently, it is not not known,
why the Jak3 and Tyk2 mutants that show enhanced autophosphorylation in vivo, are
catalytically inactive in vitro, but these results show that JH2 is in a critical position in Jaks by
regulating the activity of the tyrosine kinase domain (Chen et al., 2000; Yeh et al., 2000).
The analysis of different Jaks with differential deletions or mutations in different assay
systems produced a rather complex view of the JH2-mediated Jak regulation. Thus, it was not
clear, if the JH2 domains had different functions in the four Jak kinases. One purpose of the
current work was to compare the function of JH2 in the different Jak kinases in same
experimental settings, and by so doing, obtain information that is not available when studying
one Jak kinase at a time.
In the current work, the function of the JH2 domain was found to be conserved, to a
high degree, between Jak2 and Jak3 (II). The result that Jak3 lacking JH2 was active in this
work (II), whereas it was found inactive by others (Chen et al., 2000), highlights the importance
of critically specifying the domain boundaries used to create the deletion constructs. It is also
possible that the different results are partially due to differences between mouse (II) and human
Jak3 (Chen et al., 2000). As described above, mutations and deletions in JH2 have, surprisingly
often, produced Jak kinases with different activities. These findings collectively suggest that
the JH2 domain has a complex function in Jak kinases. In addition to its negative regulatory
role, the JH2 domain may be required for the JH1 domain to acquire its active conformation,
and the two domains may form a co-fold being linked together tightly in terms of structure and
function. The functions may be slightly different in the four Jaks, and in certain Jaks, the JH2
domain cannot be deleted without disturbing JH1.
Interestingly, despite similar inhibitory JH2 domains, the basal activity of Jak2 was
much lower than that of Jak3, indicating that the two kinases are differentially regulated (II).
The results indicate that the JH1 domains may have inherently different activities, which is in
agreement with the varying role of A-loop tyrosines in different Jaks (Gauzzi et al., 1996; Feng
et al., 1997; Liu et al., 1997; Zhou et al., 1997). These results also support the conclusion that
the deletion of JH2 may have distinct effects in different Jaks due to differential activation
requirements of the JH1 domains. The activity of the expressed Jak2 JH1 domain was also
dependent on the length of the sequence on the N-terminal side of JH1 (I).
It is also possible that conditions in the in vitro kinase assay may affect the results
obtained with Jak3 (II; Chen et al., 2000). Interestingly, a recent report on c-Abl revealed a
rather similar paradigm as found with the Tyk2 and Jak3 JH2 mutants (Chen et al., 2000; Yeh et
al., 2000; Pluk et al., 2002). Mutations in the Abl kinase had been found to result in increased
signaling in cells, but when the in vitro kinase activity of these mutant proteins was analyzed,
no difference was detected when compared to wild type c-Abl. However, when the
composition of the in vitro kinase assay buffer was changed, the mutant proteins showed
increased activity over c-Abl (Pluk et al., 2002).
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Although the results differ concerning the kinase activity of the Jak3 mutants, the role
of the JH2 domain in both positive and negative regulation of Jak activity suggested by Yeh et
al. and Chen et al. is in line with the results from the current work (II; Chen et al., 2000; Yeh et
al., 2000). Furthermore, the results from the current study may give additional explanations for
the phenotypes of the Jak3 and Tyk2 mutants (see chapters 9.4 and 9.5).
9.4 The JH2 domain is required for cytokine-dependent
activation of Jak2 and Jak3
In addition to its role as a negative regulator of Jaks, the JH2 domain was found to
positively influence Jak-mediated signaling (I, II). Specifically, while the Jak2 and Jak3 JH2
deletion mutants showed increased activity in the absence of cytokine, they failed to further
induce Stat signaling following IFN-γ and IL-2 stimulations, respectively (I, II). The JH2
domain was required to render Jaks competent to respond to cytokine stimulation with
increased activity, and thus, link cytokine-induced changes in receptor conformation to Jak
activation. Interestingly, the deletion of 13 residues in the Jak2 JH2 domain (IR3) abolished
IFN-γ-mediated induction of signaling (III). Thus, an intact JH2 domain was required for
proper regulation of Jaks in response to cytokine stimulation. This result is in agreement with
studies showing that mutations in the JH2 domains of Tyk2 and Jak3 resulted in abrogation of
cytokine signaling (Chen et al., 2000; Yeh et al., 2000).
The exact mechanism by which the JH2 domain mediates induction of Jak activity in
cytokine receptor signaling remains to be found out, but several possibilities can be considered.
The Jak2 and Jak3 JH2 deletion mutants retained catalytic activity, indicating that JH2 was not
required for kinase activity as such (I, II). JH2 could still be required for stabilizing the
activated state of JH1. Given that the Jak2 JH1 domain is extremely active compared to
full-length Jak2, this explanation may not be very likely, although it cannot be excluded.
Induction of negative feedback regulation by the constitutively active JH2 deletion
mutants is one plausible explanation for the lack of cytokine-responsiveness. Expression of
SOCS proteins, which negatively regulate cytokine signaling, is induced by many cytokines.
However, co-expression of SOCS-proteins with JH2∆-Jak2 in the Jak2-negative cell line failed
to suppress IFN-γ signaling, although signaling induced by wild-type Jak2 was significantly
reduced (unpublished observation by P. Saharinen). Furthermore, the relatively low activity of
JH2∆-Jak3 in the IL-2 receptor signaling is unlikely to result in induction of SOCS protein
expression and prevention of further signaling by IL-2 (II).
The results from the current work (I, II) showing that 1) the Jak JH2 deletion mutants
were catalytically active, 2) were able to activate Stat5 and interact with other Jaks, and 3) the
results by others that JH2 is not required for coupling Jaks to cytokine receptors, collectively
indicate that Jaks are able to interact with all these components of the signaling pathway in the
absence of JH2, but the JH2 domain is required to connect cytokine receptor activation to Jak
activation and induction of signaling. Thus, the functions of JH2 are important in the context of
the Jak-receptor complex, and suggest that the JH2 domain has an active structural role in
Jak-receptor signaling complexes during cytokine-induced activation of Jaks.
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Recent data give insight into the organization of the receptor-Jak complexes, and
indicate structural requirements in receptors for Jak activation, as outlined below. There is
increasing evidence that binding of a Jak kinase to a box1 motif of a cytokine receptor, although
required, is not sufficient for cytokine-inducible Jak activation. Instead, parts of the receptor
appear to be involved in positioning Jaks correctly, so that ligand-induced change in the
conformation of the receptor dimer allows mutual activation of Jaks. Specifically, substitution
of hydrophobic residues in the juxtamembrane region of EPOR resulted in mutant receptors
unable to activate Jak2, although binding of Jak2 to EPOR was not impaired (Constantinescu et
al., 2001; Huang et al., 2001). The hydrophobic juxtamembrane region in EPOR is predicted to
form a continuous α-helix with the transmembrane domain, and the orientation of this
juxtamembrane helix affected Jak2-mediated signaling (Constantinescu et al., 2001). Also,
physical separation of the Jak2 binding site (box1) from the precisely oriented hydrophobic
α-helix in the juxtamembrane segment abrogated activation of Jak2 signaling (Ketteler et al.,
2002). The JH7 domain in Jak2 mediates the binding to box1 of EPOR, and this interaction is
not affected by juxtamembrane mutations. Interestingly, the juxtamembrane region of EPOR is
suggested to interact with the JH1-2 domains in Jak2 during Jak activation, and consequently,
mutations in EPOR might affect this interaction (Constantinescu et al., 2001; Huang et al.,
2001).
Similarly, interaction of Jak1 with the gp130 signal transducing chain has been
analyzed. It was found that mutation of W652A in the box1 region of gp130 abolished Jak1
activation, without affecting binding of Jak1 to the receptor (Haan et al., 2002). In addition, the
relative orientation of the juxtamembrane region of gp130 was critical for Jak1-mediated
signaling (Greiser et al., 2002). Furthermore, the structural requirements of a receptor
cytoplasmic domain for Jak activation could be distinguished from those required for
Jak-mediated Stat activation (Greiser et al., 2002).
These results suggest that the organization of the ligand binding extracellular domain,
the transmembrane domain, the membrane proximal region and the Jak2 binding site (box1)
form an entity required for successful Jak activation (Ketteler et al., 2002). The activation of
Jaks is dependent on the structural determinants on cytokine receptors in a complex way, which
influences Jak activation following cytokine-induced change in the receptor complex. Thus, it
is likely that Jaks interact with cytokine receptors in at least two ways: one interaction takes
place before ligand binding and promotes cell surface expression of the specific receptor and
another interaction is involved in switching on Jak activity (Huang et al., 2001).
In the light of the data presented above, the results of the current work are suggestive of
a following model. In the resting state JH2 mediates inhibitory interaction with JH1, but
ligand-induced conformational changes in the receptor may trigger interactions between JH2
and other protein domains in the receptor complex. The JH2-mediated interactions induced by
cytokine are required for formation of the active Jak-receptor complex and progression of
signal transduction. The hydrophobic motif in the juxtamembrane domain of the EPOR
required for Jak activation, but not for initial binding to EPOR, is one potential interaction
partner for JH2 (Constantinescu et al., 2001; Huang et al., 2001). In agreement with this model,
a structural role for the Tyk2 JH2 domain has been found in the assembly of the IFNAR
complex, where Tyk2 associates with the IFNαR1 chain (Yeh et al., 2000). The Tyk2 JH2
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domain was found to be required for restoration of high-affinity IFN-α binding at the cell
surface, suggesting that Tyk2 binding in the cytoplasmic domain of IFNαR1 may affect the
ability of the extracellular domain to bind ligand (Yeh et al., 2000). However, the requirement
for Tyk2 in the IFNAR cell surface expression was not evident from Tyk2-deficient mice
(Karaghiosoff et al., 2000; Shimoda et al., 2000).
9.5 The JH2 domain in IFN-γ versus IL-2 signaling
Although the JH2 domains regulated Jak2 and Jak3 very similarly, the function of the
JH2 domain was not completely identical in IFN-γ and IL-2 signaling. When Stat activation
induced by JH2∆-Jak2 was compared to that induced by JH2∆-Jak3, a significant difference
was detected (II). Deletion of JH2 resulted in constitutive Stat activation, but this activation
was lower by JH2∆-Jak3 than by JH2∆-Jak2. Similarly, the Jak232 and Jak323 chimeras
restored inducible Stat activation by IFN-γ and IL-2, respectively, but while the Jak232
chimera behaved as wild type Jak2 in IFN-γ signaling, the Jak323 chimera was not as potent in
inducing Stat activation by IL-2 as wild-type Jak3. On the other hand, in a
receptor-independent system, the Jak323 chimera was able to induce Stat activation similarly
as wild-type Jak3. These results suggest that the JH2 domain is more critical in signaling
through the IL-2 receptor than through the IFN-γ receptor, and that the JH2 domain of Jak3 may
have a very specific role in the IL-2 receptor, which cannot be totally complemented by the
Jak2 JH2 domain.
The outcome of SCID mutations (Chen et al., 2000) and deletion of the Jak3 JH2
domain in the current work is rather similar (II). The SCID JH2 domains were found to be more
potent inhibitors of the Jak3 JH1 domain than the wild type JH2 domain, thus explaining for the
abrogation of signaling by the SCID mutations. However, in this work, the low level of
signaling is not due to increased inhibition by JH2. As discussed above, lack of functional JH2
may abrogate signaling due to the potential role of JH2 in Jak-receptor complexes. This may
also contribute to disease pathogenesis in the SCID patients by enforcing the effects of the
SCID JH2 mutations. Furthermore, the structural role of the JH2 domain may be
receptor-specific, thereby explaining for the differences found between IFN-γ and IL-2
signaling.
The result that Jak3 showed preference for Jak autophosphorylation peptides, while the
Stat5-derived peptide was a better substrate for Jak1, support a cascade model for IL-2
signaling, where Jak3 activates Jak1, which in turn phosphorylates Stat5 (II). However, Jak3
lacking functional JH2 may be defective in activation of Jak1, which might perturb
downstream signaling, thus also explaining for the critical role of JH2 in IL-2 signaling. In line
with this notion, Stat5 has been previously found to be a better substrate for Jak1 than for Jak3
(Liu et al., 1997).
Recently, Jak3 mutations occurring in the FERM domain (JH4-7) were characterized
from SCID patients (Cacalano et al., 1999; Zhou et al., 2001). These mutations impaired the
ability of Jak3 to associate with γc, and thus resulted in defective IL-2 signaling. Also, very
surprisingly, the same mutations caused inactivation of catalytic activity of Jak3, and a number
of other artificially made mutations in the FERM domain of Jak3 were found to have similar
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effects. In only one case, a mutation in Jak3 JH7 (Y100F) was found to abrogate kinase activity
without affecting binding to γc (Zhou et al., 2001). This led to a conclusion that the N-terminal
FERM domain had a role in positively regulating Jak3 activity (Zhou et al., 2001). Using a
chimeric approach, the N-terminus of Jak3 was shown to complement the inactivating
Y1034F/Y1035F double mutation in the A-loop of Jak1, also suggesting that the N-terminal
half of Jak3 could positively regulate kinase activity (Liu et al., 1997). The results from the
current work showing that JH1-2-Jak3 had lower activity than wild-type Jak3 also suggest a
positive regulatory role for the Jak3 N-terminus (II). Previously, FERM domains have been
found to mediate intra- and intermolecular protein interactions. For example, deletion of the
FERM domain in FAK resulted in hyperphosphorylation of the kinase, suggesting regulation of
FAK by the FERM domain, but somewhat differently from the regulation by that domain in
Jak3 (Schlaepfer and Hunter, 1996).
9.6 Autoregulation of Jak kinases
Inhibition of Jak2 by its JH2 domain was found to be an intrinsic property of the Jak2
molecule and not dependent on additional regulatory proteins, thereby suggesting an
autoinhibitory mechanism for JH2-mediated regulation of Jak2 (III). Autoinhibition most
likely is dependent on molecular interactions between the JH2 and JH1 domains of Jak2, as
suggested by inhibition of JH1 by co-expressed JH2 and by co-immunoprecipitation
experiments (I). However, co-immunoprecipitation between various Jak2 JH domains was
weak, therefore making it a less suitable technique for further studies. The JH2 domain of Jak3
has been also found to interact with JH1 and inhibit its activity in mammalian cells (Chen et al.,
2000).
A number of other non-receptor tyrosine kinases belonging to distinct kinase families
are regulated through autoinhibitory mechanisms, where N-terminal protein domains often
modulate the C-terminal kinase domain (reviewed in Hubbard et al., 1998). The crystal
structure of the inactive form of Src kinases, solved in 1997, revealed regulatory
protein-protein interactions, and confirmed the models of Src regulation that were based on
previous biochemical data. In c-Src and Hck, the SH2 domain interacts with a C-terminal
tyrosine residue and the SH3 domain associates with the linker between the SH2 and kinase
domains, resulting in inactive conformation of the activation loop, which blocks the
substrate-binding groove (Sicheri et al., 1997; Xu et al., 1997; Xu et al., 1999). In Btk/Tec
family kinases, Btk and Itk, the SH3 domain interacts with the N-terminal proline rich region
(Andreotti et al., 1997; Hansson et al., 2001). In c-Abl, the N-terminal region is responsible for
the inhibition of the kinase domain through intramolecular interaction (Pluk et al., 2002). The
significance of the above-described intramolecular regulation is emphasized by mutations that
abrogate the interactions resulting in ligand-independent activation of the kinases. For
example, in v-Src, the C-terminal inhibitory tyrosine residue is mutated, and this results in cell
transformation. Thus, regulation of kinase activity by intramolecular interactions appears to be
a general mechanism for non-receptor tyrosine kinases. Based on the current work (III), Jak2
can be added to the list of tyrosine kinases with autoregulatory properties. Kinetic analysis of
Jak2 activity indicated that JH2 reduced the maximal velocity (Vmax) of the kinase, but did not
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affect the Km value of Jak2 (III). This is indicative of non-competitive inhibition by the JH2
domain, and suggests that the JH2 domain may regulate Jak2 via a conformational change,
resulting in distortion of the structures essential for catalysis (III).
Deletion analysis of the Jak2 JH2 domain identified three inhibitory regions and those
refer to amino acids 618-670 (IR1), 725-757 (IR2) and 758-807 (IR3) (III). IR2 and IR3 are
located in the C lobe of JH2, while IR1 extends from the C lobe to the N lobe, as deduced from
the molecular model of the JH2 domain (Figure 11). The finding that IR3 is able to inhibit the
kinase domain alone suggests that this region may directly interact with the kinase domain. The
model structure of JH2 also suggests that IR3 may fold as an independent unit (III). IR1 and IR2
increased IR3-mediated inhibition, and it is possible that IR1 and IR2 make additional contacts
with JH1. Alternatively, IR1 and IR2 may stabilize the structure of IR3, thereby enforcing the
inhibitory function of IR3.
The previously characterized mutations in the JH2 domains of Jak2, Jak3 and Tyk2
causing aberrant kinase function, localize quite well to the inhibitory regions found in the
current work (III). The E695K substitution in the Drosophila Jak JH2 domain is
hyperactivating, and the corresponding mutation (E665K) has a similar, but less pronounced
effect in Jak2 (Luo et al., 1997; I). In the model of Jak2 JH2, E695/E665 localizes to helix D in
IR1. Two mutations in the Tyk2 JH2 domain result in constitutive Tyk2 tyrosine
phosphorylation (Yeh et al., 2000). H669P in Tyk2 corresponds to H606 in Jak2, located close
to, but outside of the N-terminal start site of IR1. R856G in Tyk2 corresponds to R795 in Jak2
located within IR3. In Jak3, the
mutations in JH2 appear to be
concentrated in the C-terminal half
of the domain (Notarangelo et al.,
2001). The C759R mutant Jak3
characterized from a SCID patient is
interesting, because it is
constitutively highly
phosphorylated (Chen et al., 2000).
In Jak2, C759 corresponds to C787
in IR3, and in Jak3 this mutation has
been predicted to disturb the
structure of the C lobe of JH2
(Vihinen et al., 2000).
The role of IR3 in regulation
of Jak2 activity was further studied
by mutational analysis. Certain, but
not all, alanine mutations in IR3
resulted in increased Jak2 activity.
Using molecular modeling, residues
763L, 764Q, 765F, E767, 771Q and
773P, showing inhibitory function
are predicted to be exposed on the
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Figure 11. Model of the three-dimensional structure of the
Jak2 JH2 domain (III).
surface of JH2, while Y766 projects inward in the model and is not likely to interact with JH1,
and consequently, may not be phosphorylated. The alanine substitutions in IR3 may distort the
α-helical structure (αG) required for inhibition, and this might affect, directly or indirectly, the
conformation of JH1.
In the EphB2 receptor tyrosine kinase, autoregulation is dependent on the interaction
between the kinase domain and a helical juxtamembrane (JM) domain on the N-terminal side of
the kinase domain (Wybenga-Groot et al., 2001). In EphB2, interaction of two juxtamembrane
helices with the kinase domain results in distortion of the N lobe and prevents the A-loop from
attaining its active conformation (Wybenga-Groot et al., 2001). The regulatory interactions in
EphB2 are mediated via conformational change alone and do not involve conventional
SH2/SH3 domain mediated interactions. The JH2-based regulation of Jak2 may rely on
interactions alike to those found in the EphB2 receptor. Intramolecular regulation in tyrosine
kinases often targets two key regulatory elements, helix C in the N lobe and the A-loop in the C
lobe (reviewed in Huse and Kuriyan, 2002). The helix C contains an important catalytic residue
(Glu 678 in the EphB2 receptor), which serves to orient the invariant lysine residue in PTKs
(Lys 661). The Lys residue, in turn, is required for correct positioning of the bound ATP. In
EphB2, the N-terminal JM domain interacts with the helix C, and induces a bend in the helix,
which removes the catalytic Glu away from its correct position (Wybenga-Groot et al., 2001).
The helix C also makes direct contacts with the A-loop, which undergoes large conformational
changes between the active and inactive states of kinases. In EphB2, the A-loop structure is
disrupted due to sterical constraints induced on the A-loop tyrosines by the JM domain. EphB2
can be activated through tyrosine phosphorylation of JM tyrosines, which disrupts the
inhibitory interactions.
The inactive conformation of many kinases can be relieved also by binding of a
substrate, which disrupts the intramolecular contacts. For example, Src family kinases can be
activated by SH2/SH3 domain containing ligands that bind to the regulatory elements in the
kinase (Moarefi et al., 1997). The requirement of the Stat SH2 domain for activation by Jak2
(Gupta et al., 1996), but not by the JH2 deletion mutant (I), suggests that the SH2 domain may
be essential for relieving the inhibited state of Jak2. Interestingly, an SH2-containing protein,
SH2-Bβ, can bind to and activate Jak2 (Rui and Carter-Su, 1999). The mechanism for SH2-Bβ
mediated activation of Jak2 is not known, but may involve the modulation of JH2 function
(O’Brien et al., 2001).
9.7 A model for the function of the JH2 domain in cytokine
signaling
Based on the results from this study (I, II, III), a model for Jak2 activation in cytokine
receptors can be envisioned (Figure 12). In the absence of cytokine stimulation, Jak2 is
associated with a monomeric cytokine receptor chain or is present in an inactive cytokine
receptor complex. In this resting state, JH2 interacts with JH1, resulting in conformational
effects that keep JH1 in an inactive conformation. Ligand binding induces a conformational
change in the receptor and brings the associated Jaks into close proximity. An activating
JH1-JH1 interaction is formed between two Jak kinases and JH1 is released from the inhibitory
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JH2 interaction, with a concomitant increase in Jak activity. At the same time, JH2 is engaged
in new types of interactions, possibly with the receptor, to enable formation of an active
receptor complex, which is required for maximal induction of Jak activity. Thus, the JH2
domain is part of both the uninduced and ligand-induced receptor complex, and may be viewed
as an inducible switch in regulating change from an inhibited to fully active state of Jak2 in
response to cytokine stimulation.
The results supporting the model are as follows. The JH2-mediated inhibition of Jak2
was found to be a property of the Jak2 kinase and independent of other regulatory proteins (III).
Kinetic analysis revealed that JH2 does not compete with substrate binding, suggesting
regulation via a conformational change (III). JH1 was found to interact more efficiently with
another JH1 than with JH2, supporting the concept that interaction between two JH1 domains is
important during activation of Jak2 (I). During juxta-positioning of Jaks upon receptor
dimerization, the “activating” intermolecular JH1-JH1 interaction would thus be preferred over
the weaker “inhibitory” intramolecular JH1-JH2 interaction, resulting in partial activation of
Jaks (III). However, for maximal Jak activation removal of JH2-mediated inhibition is not
sufficient, since catalytically active JH2 deletion mutants are unable to respond to cytokine
stimulation (II). Instead, JH2 needs to build up an active Jak-receptor complex where Jak
activation can be induced. The role of JH2 might be in proper construction of the receptor
complex or to stabilize the activated state of Jaks. The first explanation is favoured, since JH1,
lacking JH2, has significantly higher activity than Jak2 (I). Therefore, it is likely, that in
addition to its interaction with JH1, JH2 interacts with other proteins, protein domains or even
non-protein ligands to mediate its dual regulatory function in cytokine receptors. This
interaction may be receptor-specific, since Jak2 and Jak3 JH2 domains showed preference over
the two receptor models tested (II). The model presented here for the function of the
pseudokinase domain is in line, and gives additional explanations for the results obtained by
other groups using Tyk2 and Jak3 mutants derived from SCID patients (Chen et al., 2000; Yeh
et al., 2000).
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Figure 12. A schematic model for the function of the JH2 domain in cytokine signaling by Jak kinases, see
text for details.
10 PERSPECTIVE
With the almost completion of the Human Genome Project, the total number of tyrosine
kinases in the human genome is 90, of which 32 are of non-receptor type, including the four Jak
kinases and five Tec kinases (Robinson et al., 2000). During the last five years, the crystal
structures for many tyrosine kinases have been solved. This has increased the understanding of
tyrosine kinase function enormously, especially, how the activity of these central signal
transduction proteins is regulated, with implications in drug development for the treatment of a
variety of diseases.
Understanding the activation of cytokine signaling at a molecular level is of
importance, since cytokines play a central role in so many physiological processes, and there is
often interest to modulate these processes. The current study shows that Jak kinases are
autoinhibited through their pseudokinase domains (I II, III), a unique feature of Jak kinases.
This regulation takes place in a situation, where cells are deprived from cytokines (I, II). Upon
cytokine stimulation, the cytokine receptor undergoes a change into an active conformation,
and the Jak kinases are activated simultaneously. The results from this work (I, II) suggest that
the pseudokinase domain links receptor activation to activation of Jak kinases.
The increased knowledge of the receptor epitopes required for Jak activation and the
large number of different mutations in the JH2 domains of Jaks that abolish cytokine-inducible
signaling, suggests that a Jak kinase forms a fine-tuned complex with the receptor, where small
disturbances abrogate effective signaling. Results showing that Jaks enhance cell surface
expression of certain of the cytokine receptors, and that the cytoplasmic reagion of EPOR does
not fold properly in the absence of Jak2 (Remy et al., 1999), also suggest a structural role for
Jaks in cytokine receptors. Thus, the receptors and Jaks may be viewed as forming one
functional entity much like receptor tyrosine kinases.
One of the major questions waiting to be solved concerning Jak kinases is their
three-dimensional structure, which will very likely reveal the mechanism of their
autoinhibition. Of high interest is also the three-dimensional structure of a cytoplasmic domain
of a cytokine receptor, which has not been solved either. Finally, structural knowledge of the
complex between a receptor and a Jak kinase will be of importance in understanding the tight
connection between activation of a cytokine receptor and a Jak kinase.
The increasing data of constitutive Stat activation in a variety of cancers indicates Stats
as potential targets for drug discovery. Since Stat activation is dependent on upstream tyrosine
kinases, the kinases themselves appear as drugable targets as well, in cases, where a connection
between a PTK and Stat is known. The Bmx and Jak2 tyrosine kinases are among the potential
targets for future therapeutics.
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